CINXE.COM

<!DOCTYPE html> <html lang="en-us" class="cdc-2022 theme-indigo cdc-tp5" > <head> <meta charset="utf-8" /> <meta http-equiv="X-UA-Compatible" content="IE=Edge" /> <meta content="width=device-width, initial-scale=1, shrink-to-fit=no" name="viewport" /> <meta name="mobile-web-app-capable" content="yes" /> <meta name="apple-mobile-web-app-capable" content="yes" /> <meta name="theme-color" content="#075290"> <link rel="apple-touch-icon" sizes="180x180" href="/TemplatePackage/4.0/assets/imgs/favicon/apple-touch-icon.png"> <link rel="icon" type="image/png" sizes="32x32" href="/TemplatePackage/4.0/assets/imgs/favicon/favicon-32x32.png"> <link rel="icon" type="image/png" sizes="16x16" href="/TemplatePackage/4.0/assets/imgs/favicon/favicon-16x16.png"> <link rel="mask-icon" href="/TemplatePackage/4.0/assets/imgs/favicon/safari-pinned-tab.svg" color="#0056b3"> <meta name="msapplication-TileColor" content="#0056b3"> <meta name="theme-color" content="#0056b3"> <link rel="stylesheet prefetch" href="/TemplatePackage/contrib/libs/bootstrap/latest/css/bootstrap.min.css?_=79008" /> <link rel="stylesheet prefetch" href="/TemplatePackage/4.0/assets/css/app.tp5.min.css?_=79008" /> <link rel="stylesheet" media="print" href="/TemplatePackage/4.0/assets/css/print.min.css?_=79008" />  <script src="https://www.cdc.gov/JScript/metrics/topic_levels.js?_=79008"></script> <script src="https://www.cdc.gov/JScript/metrics/adobe/launch/b36c1852e229/2c674008a127/launch-04da70ea688d.min.js" async></script> <title>Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 ― United States, January–July 2022 | MMWR</title> <meta name="description" content="This report describes racial and ethnic disparities in outpatient treatment of COVID-19 in the United States."/> <meta property="og:title" content="Racial and Ethnic Disparities in Outpatient Treatment ..."> <meta property="og:description" content="This report describes racial and ethnic disparities in outpatient treatment of COVID-19 in the United States."> <meta property="fb:app_id" content="205691699516606"> <meta property="og:url" content="https://www.cdc.gov/mmwr/volumes/71/wr/mm7143a2.htm"> <meta property="og:image" content="https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7143a2_COVIDTreatmentDisparities_IMAGE_28Oct22_1200x675.jpg"> <meta property="og:image:type" content="image/jpeg"> <meta property="article:published_time" content="2022-10-27"> <meta property="og:author" content="CDC"> <meta property="article:author" content="CDCMMWR"> <meta property="og:site_name" content="Centers for Disease Control and Prevention"> <meta property="og:type" content="article"> <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:site" content="@CDCMMWR"> <meta name="twitter:creator" content="@CDCgov"> <meta name="twitter:title" content="Racial and Ethnic Disparities in Outpatient Treatment ..."> <meta name="twitter:description" content="This report describes racial and ethnic disparities in outpatient treatment of COVID-19 in the United States."> <meta name="twitter:domain" content="https://www.cdc.gov/mmwr/volumes/71/wr/mm7143a2.htm?s_cid=mm7143a2_w"> <meta name="twitter:image:src" content="https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7143a2_COVIDTreatmentDisparities_IMAGE_28Oct22_1200x675.jpg"> <meta name="robots" content="index, archive" /> <meta property="cdc:template_version" content="4.0"/> <meta property="cdc:first_published" content="October 27, 2022"/> <meta property="cdc:last_updated" content="October 27, 2022, 01:00 PM"/> <meta property="cdc:last_reviewed" content="October 27, 2022"/> <meta property="cdc:content_source" content="SCIENTIFIC PUBLICATIONS BRANCH"/> <meta property="cdc:maintained_by" content="SCIENTIFIC PUBLICATIONS BRANCH"/> <meta property="cdc:content_id" content="100864" /> <meta property="cdc:build" content="3257" /> <meta property="cdc:version" content="4.24.3" /> <meta property="cdc:page_type" content="cdc_mmwr" /> <meta property="cdc:page_origin" content="wcms"/> <meta name="citation_categories" content="Full Report"/><meta name="citation_title" content="Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 ― United States, January–July 2022"/><meta name="citation_author" content="Tegan K. Boehmer"/><meta name="citation_publication_date" content="2022"/><meta name="citation_journal_title" content="MMWR. Morbidity and Mortality Weekly Report"/><meta name="citation_journal_abbrev" content="MMWR Morb Mortal Wkly Rep"/><meta name="citation_issn" content="0149-21951545-861X"/><meta name="citation_volume" content="71"/><meta name="citation_doi" content="10.15585/mmwr.mm7143a2"/><meta name="Description" content="This report describes racial and ethnic disparities in outpatient treatment of COVID-19 in the United States."/> <link rel="canonical" href="https://www.cdc.gov/mmwr/volumes/71/wr/mm7143a2.htm"/> <meta property="cdc:wcms_build" content="4.24.3 - b.3257" /> <link rel="stylesheet" type="text/css" href="/mmwr/volumes/wcms-inc/local.css?v=3257"/>  <meta name="DC.date" content="2022-10-26T05:05:00Z" /> <meta name="cdc:last_published" content="2024-04-23T19:14:12Z" /> </head> <body class="no-js cdc-mmwr"> <div id="skipmenu"> <a class="skippy sr-only-focusable" href="#content">Skip directly to site content</a> <a class="skippy sr-only-focusable" href="#headerSearch">Skip directly to search</a> </div> <div class="header-language-bar container text-right pt-1 pb-1 fs0875"> <a href="/spanish/"><span lang="es-us">Español</span></a><span class="link-divider"> | </span> <a href="https://wwwn.cdc.gov/pubs/other-languages/">Other Languages</a> </div> <div class="cdc-header-official-notice container noindex"> <div class="cdc-header-official-notice-header d-flex"> <img src="/TemplatePackage/4.0/assets/imgs/uswds/us_flag_small.png" width="16" height="11" alt="U.S. flag" /> <small class="ml-2">An official website of the United States government <button class="cdc-header-official-notice-header-btn">Here's how you know <span class="cdc-header-official-notice-header-icon x12 fill-p cdc-icon-arrow-down"></span></button></small> </div> <div class="cdc-header-official-notice-body row" style="display: none;"> <figure class="col-lg-6 d-flex"> <img class="cdc-header-official-notice-body-img" src="/TemplatePackage/4.0/assets/imgs/uswds/icon-dot-gov.svg" alt="Official icon" aria-hidden="true" /> <figcaption class="cdc-header-official-notice-body-info ml-3"> <p class="cdc-header-official-notice-body-title mb-1"><strong>Official websites use .gov</strong></p> <p>A .gov website belongs to an official government organization in the United States.</p> </figcaption> </figure> <figure class="col-lg-6 d-flex"> <img class="cdc-header-official-notice-body-img" src="/TemplatePackage/4.0/assets/imgs/uswds/icon-https.svg" alt="Lock icon" aria-hidden="true" /> <figcaption class="cdc-header-official-notice-body-info ml-3"> <p class="cdc-header-official-notice-body-title mb-1"><strong>Secure .gov websites use HTTPS</strong></p> <p>A lock ( <span class="x16 fill-black cdc-icon-lock-alt-solid"></span> ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.</p> </figcaption> </figure> </div> </div> <header id="page_banner" role="banner" aria-label="Banner"> <div class="container-fluid header-wrapper"> <div class="container"> <div class="row py-2"> <div class="col cdc-logo"> <a href="https://www.cdc.gov/"> <span class="sr-only">Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People</span> <img src="/TemplatePackage/4.0/assets/imgs/logo/logo-notext.svg" alt="CDC Logo" class="cdc-logo--desktop"> <img src="/TemplatePackage/4.0/assets/imgs/logo/logo-notext.svg" alt="CDC Logo" class="cdc-logo--mobile"> </a> </div> <div class="col-2 col-md-3 col-xl-5 col-xxl-4 tp-search"> <div class="headerSearch cdc-header-search"> <form accept-charset="UTF-8" action="https://search.cdc.gov/search/" class="cdc-header-search-form" method="get" autocomplete="off">  <button class="btn btn-primary dropdown-toggle no-toggle search-button ssi d-xl-none" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" aria-label="search"><span>Search</span> <i class="fi cdc-icon-magnify dropdown-menu-medium-search-icon x24" aria-hidden="true"></i> <i class="fi cdc-icon-close dropdown-menu-medium-close-icon x24" aria-hidden="true"></i> </button> <div class="dropdown-menu dropdown-menu-right dropdown-menu-search dropdown-menu-medium-search"> <div class="input-group"> <input id="headerSearch" type="text" class="form-control" maxlength="300" placeholder="Search" aria-label="Search" name="query"> <span class="form-control-clear cdc-icon-close"></span> <div class="input-group-append"> <button class="btn search-submit" type="button"> <span class="sr-only">Submit</span> <i class="fi cdc-icon-magnify x24 search-submit" aria-hidden="true"></i> </button> </div> </div> </div> <input type="hidden" name="affiliate" value="cdc-main"> </form> </div> </div> </div> </div> </div> <div class="container-fluid site-title"> <div class="container"> <div class="row"> <div class="col"> <div class="display-6 text-white fw-500 pt-1 pb-1 site-title-inner "> <a href="/mmwr/index.html"> Morbidity and Mortality Weekly Report (<em>MMWR</em>)</a> </div> </div> </div> </div> </div> <nav role="navigation" aria-label="Mobile Nav" id="mobilenav" class="sticky-top"> </nav>  <div class="container-fluid feature-area"> <div class="container"></div> </div> </header> <div class="container d-flex flex-wrap body-wrapper bg-white"> <main class="col-12 order-lg-2" role="main" aria-label="Main Content Area"> <div class="row visual-element"> <div class="col"> </div> </div> <div class="section-nav-area"> <nav role="navigation" aria-label="Section Nav" class="w-100 sticky-top"></nav> </div> <div class="row"> <div class="col content content-fullwidth"> <h1>Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 ― United States, January–July 2022</h1> <div class="dateline"> <p><em>Weekly</em> / October 28, 2022 / 71(43);1359–1365 </p> </div> <div class="title-bar"> <a href="#print" class="print-link" aria-label="print this page" onclick="window.print()">Print</a> </div> <div class="mb-3 card tp-related-pages fourth-level-nav d-none"> <div class="card-header collapse-icon"> <a class="collapse-link float-right nav-minus fs0875" data-toggle="collapse" href="#collapse_10086466280883e1e1a" aria-expanded="false" aria-controls="collapse_10086466280883e1e1a"> <svg viewBox="0 0 24 24" focusable="false" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"> <title>Minus</title> <path d="M19,13H5V11H19V13Z"></path> </svg> </a> <div class="h4">Related Pages</div> </div> <div class="card-body collapse show" id="collapse_10086466280883e1e1a"></div> </div> <div class="syndicate"> <div class="d-flex flex-wrap d-md-block"> <div class="order-3 mb-3"><p>Tegan K. Boehmer, PhD<sup>1</sup>; Emily H. Koumans, MD<sup>1</sup>; Elizabeth L. Skillen, PhD<sup>1</sup>; Michael D. Kappelman, MD<sup>2</sup>; Thomas W. Carton, PhD<sup>3</sup>; Aditiben Patel, MPH<sup>1</sup><sup>,4</sup>; Euna M. August, PhD<sup>5</sup>; Ryan Bernstein<sup>1</sup><sup>,4</sup>; Joshua L. Denson, MD<sup>6</sup>; Christine Draper<sup>7</sup>; Adi V. Gundlapalli, MD, PhD<sup>1</sup>; Anuradha Paranjape, MD<sup>8</sup>; Jon Puro, MHA<sup>9</sup>; Preetika Rao, MPH<sup>1</sup>; David A. Siegel, MD<sup>1</sup>; William E. Trick, MD<sup>10</sup>; Chastity L. Walker, DrPH<sup>11</sup>; Jason P. Block, MD<sup>7</sup> (<a class="h6" style="font-weight: normal" href="#contribAff">View author affiliations</a>)</p> <a class="mb-md-3" href="#suggestedcitation">View suggested citation</a></div><div class="bg-gray-l2 col-md-9 float-left mb-3 order-0 "><h3><strong>Summary</strong></h3> <p><strong>What is already known about this topic?</strong></p> <p>Outpatient medications are effective at preventing severe COVID-19 and are important to pandemic mitigation. Paxlovid is the most commonly prescribed medication and the preferred outpatient therapeutic for eligible patients.</p> <p><strong>What is added by this report?</strong></p> <p>Racial and ethnic disparities persisted in outpatient COVID-19 treatment through July 2022. During April–July 2022, the percentage of COVID-19 patients aged ≥20 years treated with Paxlovid was 36% and 30% lower among Black and Hispanic patients than among White and non-Hispanic patients, respectively. These disparities existed among all age groups and patients with immunocompromise.</p> <p><strong>What are the implications for public health practice?</strong></p> <p>Expansion of programs to increase awareness of and access to available outpatient COVID-19 treatments can help protect persons at high risk for severe illness and facilitate equitable health outcomes.</p> </div><div class="col-md-3 float-right order-12 mt-3 mt-md-0 no-syndicate "> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <style type="text/css"> .altmetric-embed.mt-2.mb-3 > div { display: flex; } </style> <div class="card mb-3" data-mmwr-metrics="article"> <div class="card-header h4 bg-primary">Article Metrics</div> <div class="card-body bg-white"> <h5>Altmetric:</h5> <div class="altmetric-embed mt-2 mb-3" data-badge-details="right" data-badge-type="donut" data-condensed="true" data-hide-no-mentions="true" data-link-target="_blank"></div> <div class="border-top mt-2 mb-2"></div> <h5>Citations: <span class="mmwr_citations"></span></h5> <div class="border-top mt-2 mb-3"></div> <h5>Views: <span class="mmwr_total_views"></span> <p class="small pt-1"><em>Views equals page views plus PDF downloads</em></p> </h5> <div class="text-right"> <a href="#" class="btn btn-primary btn-sm" role="button" data-toggle="modal" data-target="#articleMetricModal">Metric Details</a> </div> </div> </div> </div><div class="col-md-3 float-right d-none d-md-block cr mb-3"><div class="card theme-cyan bg-gray-l2"><div class="card-header"><a href="#F1_down"><strong>Figure</strong></a></div></div></div><div class="col-md-3 float-right d-none d-md-block cr mb-3"><div class="card theme-cyan bg-gray-l2"><div class="card-header"><strong>Tables</strong></div><div class="card-body"><p><a href="#T1_down">Table 1</a></p><p><a href="#T2_down">Table 2</a></p></div></div></div><div class="col-md-3 float-right mb-3 cr order-1"><div class="card mb-3"><div class="card-header h4 bg-primary">Related Materials</div><div class="card-body"><ul class="mb-0 block-list"><li><a href="/mmwr/volumes/71/wr/pdfs/mm7143a2-H.pdf" target="_blank">PDF <span aria-label="pdf icon" class="sr-only" role="img"></span><span class="fi cdc-icon-pdf x16 fill-pdf" alt="" aria-hidden="true"></span><span class="file-details">[168K]</span></a></li></ul></div></div></div><div class="order-4 w-100"><p>In December 2021 and early 2022, four medications received emergency use authorization (EUA) by the Food and Drug Administration for outpatient treatment of mild-to-moderate COVID-19 in patients who are at high risk for progressing to severe disease; these included nirmatrelvir/ritonavir (Paxlovid) and molnupiravir (Lagevrio) (both oral antivirals), expanded use of remdesivir (Veklury; an intraveneous antiviral), and bebtelovimab (a monoclonal antibody [mAb]).* Reports have documented disparities in mAb treatment by race and ethnicity (<i>1</i>) and in oral antiviral treatment by zip code–level social vulnerability (<i>2</i>); however, limited data are available on racial and ethnic disparities in oral antiviral treatment.<sup>&dagger;</sup> Using electronic health record (EHR) data from 692,570 COVID-19 patients aged ≥20 years who sought medical care during January–July 2022, treatment with Paxlovid, Lagevrio, Veklury, and mAbs was assessed by race and ethnicity, overall and among high-risk patient groups. During 2022, the percentage of COVID-19 patients seeking medical care who were treated with Paxlovid increased from 0.6% in January to 20.2% in April and 34.3% in July; the other three medications were used less frequently (0.7%–5.0% in July). During April–July 2022, when Paxlovid use was highest, compared with White patients, Black or African American (Black) patients were prescribed Paxlovid 35.8% less often, multiple or other race patients 24.9% less often, American Indian or Alaska Native and Native Hawaiian or other Pacific Islander (AIAN/NHOPI) patients 23.1% less often, and Asian patients 19.4% less often; Hispanic patients were prescribed Paxlovid 29.9% less often than non-Hispanic patients. Racial and ethnic disparities in Paxlovid treatment were generally somewhat higher among patients at high risk for severe COVID-19, including those aged ≥50 years and those who were immunocompromised. The expansion of programs focused on equitable awareness of and access to outpatient COVID-19 treatments, as well as COVID-19 vaccination, including updated bivalent booster doses, can help protect persons most at risk for severe illness and facilitate equitable health outcomes.</p> <p>This study used EHR data from 30 sites (each representing one or more health care systems) participating in PCORnet, the National Patient-Centered Clinical Research Network (PCORnet).<sup>§</sup> The PCORnet distributed data infrastructure was queried<sup>¶</sup> and returned aggregate demographic and clinical data for all COVID-19 patients and those treated with Paxlovid, Lagevrio, Veklury,** or mAbs<sup>&dagger;&dagger;</sup> during January–July 2022. COVID-19 patients were persons aged ≥20 years who sought medical care and had EHR documentation of a positive SARS-CoV-2 viral test result, an <i>International Classification of Diseases, Tenth Revision, Clinical Modification</i> (ICD-10-CM) diagnostic code for COVID-19 (U07.1 and U07.2), or treatment with an assessed COVID-19 medication.<sup>§§</sup> Treated COVID-19 patients had EHR documentation of a Paxlovid or Lagevrio prescription or Veklury or mAb administration.<sup>¶¶</sup> High-risk patient groups were defined based on age (50–64, 65–79, and ≥80 years) and immunocompromise (previous organ transplant, active cancer treatment, corticosteroid use, and immunosuppressive medication use).***</p> <p>The percentage of COVID-19 patients treated with each medication was calculated by age group, sex (male and female), race (White, Black, Asian, AIAN/NHOPI, multiple or other race, and missing), ethnicity (Hispanic, non-Hispanic, and other or missing),<sup>&dagger;&dagger;&dagger;</sup> immunocompromise, and underlying medical conditions.<sup>§§§</sup> Disparities were assessed using absolute differences (percentage treated in the racial or ethnic minority group minus the percentage treated in the majority group [i.e., White race and non-Hispanic ethnicity, respectively]) and relative differences (absolute difference divided by the percentage treated in the majority group). Statistical differences in the percentage treated by race and ethnicity were quantified using Pearson’s chi-square tests comparing patients in the minority groups with those in the majority group. Disparities in percentage treated overall and by age group were assessed during April–July 2022, when Paxlovid use was highest; disparities by immunocompromise could only be assessed during January–July 2022 because of restrictions in the PCORnet distributed data infrastructure. P-values <0.05 were considered statistically significant. This activity was reviewed by CDC and conducted consistent with applicable federal law and CDC policy.<sup>¶¶¶</sup></p> <p>During January–July 2022, a total of 692,570 COVID-19 patients aged ≥20 years were identified.**** Among these, 22.2% were aged ≥65 years, 60.5% were female, 68.2% were White, and 79.6% were non-Hispanic (<a id="T1_up"></a><a href="#T1_down">Table 1</a>). Overall, 11.7% of COVID-19 patients were treated with Paxlovid, 2.7% with mAbs, 1.0% with Lagevrio, and 0.7% with Veklury. The percentage treated with Paxlovid exceeded the overall average of 11.7% for the following patient groups: aged ≥50 years, White, non-Hispanic,<sup>&dagger;&dagger;&dagger;&dagger;</sup> active cancer treatment, corticosteroid use, immunosuppressive medication use, and presence of underlying medical conditions (except chronic kidney disease, cirrhosis, congestive heart failure, and dementia). mAb treatment was more common than Paxlovid treatment among patients with a previous organ transplant.</p> <p>During 2022, the percentage of COVID-19 patients treated with Paxlovid increased from 0.6% in January to 20.2% in April and 34.0% in July (Supplementary Figure, <a href="https://stacks.cdc.gov/view/cdc/121864">https://stacks.cdc.gov/view/cdc/121864</a>). Treatment with other medications occurred less frequently and varied less during the study period (mAbs [monthly range = 1.2%–5.0%], Lagevrio [0.4%–2.5%], and Veklury [0.6%–0.9%]). Racial and ethnic differences in monthly Paxlovid treatment were observed (<a id="F1_up"></a><a href="#F1_down">Figure</a>).</p> <p>During April–July 2022, Paxlovid treatment among adults aged ≥20 years was 35.8% lower among Black patients (20.5% treated) than it was among White patients (31.9% treated) (<a id="T2_up"></a><a href="#T2_down">Table 2</a>). Paxlovid treatment was 24.9%, 23.1%, and 19.4% lower among multiple or other race, AIAN/NHOPI, and Asian patients, respectively, than among White patients, and 29.9% lower among Hispanic than among non-Hispanic patients. In age-stratified analyses, the percentage of patients aged 20–49, 50–64, 65–79, and ≥80 years who were prescribed Paxlovid was 20.9%, 34.3%, 39.9%, and 30.7%, respectively. Disparities for Black, multiple or other race, and Hispanic patients were present across all age strata; the largest relative difference (44.0%) was between Black and White patients aged 65–79 years.</p> <p>Racial and ethnic disparities existed for treatment with other medications, but absolute differences were small, given the low treatment percentages. Racial and ethnic minority patients were treated with mAbs and Lagevrio less often than were White and non-Hispanic patients (Supplementary Table 1, <a href="https://stacks.cdc.gov/view/cdc/121865">https://stacks.cdc.gov/view/cdc/121865</a>). AIAN/NHOPI, Asian, and Hispanic patients received Veklury less often than did White and non-Hispanic patients; Black patients received Veklury more often than White patients.</p> <p>During January–July 2022, racial and ethnic disparities also existed for the four immunocompromised patient groups. In general, immunocompromised Black, multiple or other race, and Hispanic patients were treated with Paxlovid and mAbs less often than were immunocompromised White and non-Hispanic patients. Treatment differences between immunocompromised White and both AIAN/NHOPI and Asian patients were small or not statistically significant (Supplementary Table 2, <a href="https://stacks.cdc.gov/view/cdc/121865">https://stacks.cdc.gov/view/cdc/121865</a>).</p> </div><div class="order-4"><p class="text-right"><a href="#">Top</a></p></div><div class="order-4 w-100"><div> <h2><a id="discussion" class="onThisPageAnchor" title="Discussion"></a>Discussion</h2> <p>In this study of nearly 700,000 COVID-19 patients who sought medical care, the proportion who were treated with an outpatient COVID-19 medication increased substantially over time, primarily driven by increased Paxlovid use; however, treatment gaps exist among racial and ethnic minority groups. During April–July 2022, Paxlovid treatment was 35.8% lower among Black patients relative to White patients and 29.9% lower among Hispanic patients relative to non-Hispanic patients. This study corroborates previous reports of inequitable outpatient COVID-19 treatment (<i>1</i>,<i>2</i>) and documents the persistence of racial and ethnic disparities through July 2022. Disparities in pharmacy dispensing of oral antiviral medications between zip codes with high and with low social vulnerability began narrowing during July–August 2022, after the current study ended (<i>3</i>). Additional analyses can determine whether this recent ecological trend will result in reduced racial and ethnic disparities.</p> <p>Multiple factors likely contributed to the observed disparities. Persons living in counties that are both high-poverty areas and majority Black, Hispanic, or American Indian or Alaska Native are less likely to have access to COVID-19 treatment facilities.<sup>§§§§</sup> Limited access to treatment is particularly detrimental when patients need timely services, as is required for COVID-19 medications that must be initiated soon after symptom onset (5 days for oral antivirals, 7 days for mAbs and Veklury, as authorized by EUAs). In addition, minority patients’ previous negative experiences with health care services could influence their decisions regarding use of treatments (<i>4</i>), or racism and implicit biases among health care providers might have contributed to treatment disparities (<i>5</i>). Race and ethnicity also could be proxies for other barriers, such as limited knowledge of treatment options, lack of internet access for telemedicine services (<i>6</i>), limited transportation, and language barriers (<i>7</i>).</p> <p>Lessons learned from the COVID-19 pandemic<sup>¶¶¶¶</sup> offer opportunities to reduce outpatient treatment disparities (<i>8</i>), including prioritizing medication distribution to and raising awareness about treatment options among local health care providers and members of disproportionately affected communities. Communication campaigns, especially those that use trusted messengers, have been effective in reaching racial and ethnic minority populations and might facilitate increased awareness and use of COVID-19 treatments (<i>9</i>). Several initiatives have been implemented at the federal and state levels to improve equitable dispensing of COVID-19 medications (<i>3</i>). One example is the federal Test-to-Treat initiative that provides COVID-19 testing, medical evaluation, and treatment at a single location and was expanded in May 2022 to better reach vulnerable communities.*****</p> <p>The findings in this report are subject to at least six limitations. First, the aggregate data structure did not allow for adjustment of demographic or clinical factors that might be correlated with race and ethnicity or for assessment of combined race and ethnicity over time. Second, this study assessed treatment disparities among COVID-19 patients who sought medical care; the percentage treated and magnitude of disparities among COVID-19 patients who are eligible for treatment or among all persons with COVID-19 is unknown. Third, patients treated with oral antiviral medications at community treatment programs (e.g., Test-to-Treat) were not captured in this study; thus, actual disparities could be lower than those reported if community treatment programs were differentially used by racial and ethnic minority groups. Fourth, the reasons for nontreatment (e.g., too long since symptom onset, not at risk for severe illness, treatment not offered, or treatment refused) are unknown. Fifth, small sample sizes for some race and immunocompromised patient groups led to unstable estimates. Finally, PCORnet data are derived from a convenience sample of health care facilities and captured approximately 2% of COVID-19 patients reported to CDC during January–July 2022; thus, the results might not be nationally generalizable.</p> <p>Early access to effective COVID-19 treatments and staying up to date with COVID-19 vaccination, including use of updated bivalent boosters,<sup>&dagger;&dagger;&dagger;&dagger;&dagger;</sup> are critical components of the public health response to the pandemic, especially for protecting persons most at risk for severe illness (<i>10</i>). Racial and ethnic disparities persist in outpatient COVID-19 treatment, even among older adults and patients with immunocompromise. Expansion of programs focused on equitable outpatient COVID-19 treatment, including raising patient awareness using trusted sources, educating clinicians and other prescribers, and expanding patient access to prescribers, can facilitate equitable health outcomes.</p> </div> </div><div class="order-4"><p class="text-right"><a href="#">Top</a></p></div><div class="order-4 w-100"><p>Corresponding author: Tegan K. Boehmer, <a href="mailto:tboehmer@cdc.gov">tboehmer@cdc.gov</a>.</p> </div><div class="order-4"><p class="text-right"><a href="#">Top</a></p></div><hr style="border-top:1px solid"><div class="order-4 w-100"><p><a id="contribAff"></a><sup>1</sup>CDC COVID-19 Emergency Response Team; <sup>2</sup>Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina; <sup>3</sup>Louisiana Public Health Institute, New Orleans, Louisiana; <sup>4</sup>Booz Allen Hamilton, Inc., McLean, Virginia; <sup>5</sup>Office of Minority Health and Health Equity, CDC; <sup>6</sup>Section of Pulmonary Diseases, Critical Care, and Environmental Medicine, Tulane University School of Medicine, New Orleans, Louisiana; <sup>7</sup>Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, Massachusetts; <sup>8</sup>Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania; <sup>9</sup>OCHIN, Inc., Portland, Oregon; <sup>10</sup>Center for Health Equity and Innovation, Cook County Health, Chicago, Illinois; <sup>11</sup>National Center for Immunization and Respiratory Diseases, CDC.</p> </div><div class="order-4"><p class="text-right"><a href="#">Top</a></p></div><div class="order-4 w-100"><div class="footnote-text"> <p class="Footnote">All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. William E. Trick reports institutional support from PCORnet, the National Patient-Centered Clinical Research Network. Anuradha Paranjape reports serving as the uncompensated president of the Association of Chiefs & Leaders of General Internal Medicine. Michael D. Kappelman reports consulting fees from Abbvie, Takeda, Janssen, and Pfizer, and stock ownership in Johnson & Johnson. Joshua L. Denson reports research funding from the American Diabetes Association, the Society of Critical Care Medicine, and the National Institutes of Health (NIH) (Grant funding the Louisiana Clinical and Translational Science Center Roadmap Scholars Award). Thomas W. Carton and Jason P. Block report grant support from NIH, as part of the Researching COVID to Enhance Recovery (RECOVER) research program. No other potential conflicts of interest were disclosed.</p> </div> </div><div class="order-4"><p class="text-right"><a href="#">Top</a></p></div><br><div class="order-4 w-100"><div class="footnote-text"> <p class="Footnote">* Paxlovid and Lagevrio received Food and Drug Administration EUA in late December 2021, Veklury in January 2022 (for outpatient use), and bebtelovimab in February 2022. mAb treatments that previously received EUAs for treatment of COVID-19 had those EUAs revoked when they were no longer effective against SARS-CoV-2 variants. <a href="https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs" class="tp-link-policy" data-domain-ext="gov">https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></p> <p class="Footnote"><sup>&dagger;</sup> <a href="https://www.medrxiv.org/content/10.1101/2022.06.22.22276782v2" class="tp-link-policy" data-domain-ext="org">https://www.medrxiv.org/content/10.1101/2022.06.22.22276782v2<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></p> <p class="Footnote"><sup>§</sup> PCORnet is a national network of networks that facilitates access to health care data and interoperability through use of a common data model across participating sites (<a href="https://pcornet.org/data" class="tp-link-policy" data-domain-ext="org">https://pcornet.org/data<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a>). These sites represent academic and community health care systems serving self-pay or publicly or privately insured patients. The list of 30 PCORnet sites that provided data is available through download. <a href="https://github.com/PCORnet-DRN-OC/Query-Details/tree/master/Therapeutics%20Query" class="tp-link-policy" data-domain-ext="com">https://github.com/PCORnet-DRN-OC/Query-Details/tree/master/Therapeutics%20Query<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></p> <p class="Footnote"><sup>¶</sup> A query is a single statistical program package that runs at participating PCORnet sites to generate aggregate site-level data; results are returned to the PCORnet coordinating center and combined into a single aggregate report with data from all responding sites.</p> <p class="Footnote">** To the extent possible, Veklury treatment was restricted to outpatient administration as approved under the January 2022 EUA; patients hospitalized during the 7 days before or after the administration of Veklury were excluded from the assessment. Among 4,721 patients treated with Veklury, 61% had an emergency department and 16% had an inpatient encounter in the 14 days before or after the administration.</p> <p class="Footnote"><sup>&dagger;&dagger;</sup> Among 18,949 patients treated with mAbs, 11,729 (62%) received bebtelovimab, 6,379 (34%) received sotrovimab (EUA revoked April 2022), and 1,084 (6%) received other mAbs (bamlanivimab [EUA revoked April 2021]; bamlanivimab/etesevimab or casirivimab/imdevimab [EUAs revoked January 2022]). A small percentage of patients (243; 1%) had documentation of treatment with more than one mAb.</p> <p class="Footnote"><sup>§§</sup> SARS-CoV-2 viral tests included nucleic acid amplification test/polymerase chain reaction (NAAT/PCR) (96%) and rapid antigen (4%) tests. National Drug Code and RxNorm codes were used to identify medication prescriptions (Paxlovid and Lagevrio) and administrations (mAb and Veklury) and ICD-10 Procedure Coding System and Healthcare Common Procedure Coding System/Current Procedural Terminology codes were used to identify mAb and Veklury administrations. Codes are available through download. <a href="https://github.com/PCORnet-DRN-OC/Query-Details/tree/master/Therapeutics%20Query" class="tp-link-policy" data-domain-ext="com">https://github.com/PCORnet-DRN-OC/Query-Details/tree/master/Therapeutics%20Query<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></p> <p class="Footnote"><sup>¶¶</sup> Treatment groups were not mutually exclusive. For example, among 81,373 patients prescribed Paxlovid, 579 (0.7%) were also treated with mAbs (491 bebtelovimab), 619 (0.8%) with Lagevrio, and 203 (0.2%) with Veklury. Among patients prescribed Paxlovid, 71% had either a diagnostic code for COVID-19 or a documented positive SARS-CoV-2 viral test (NAAT/PCR or rapid antigen); 28% had a documented positive viral test, and 66% had a diagnostic code. There were no systematic differences in age, sex, race, or ethnicity between patients prescribed Paxlovid who had a diagnostic code or positive test compared with those who did not.</p> <p class="Footnote">*** The presence of immunocompromise was based on available information in the patients’ EHR before COVID-19: previous organ transplant (one or more ICD-10-CM codes at any time before COVID-19); active cancer treatment (three or more ICD-10-CM codes for cancer during the 6 months preceding COVID-19); corticosteroid use (two or more prescriptions during the year preceding COVID-19); and immunosuppressive medication use (one or more prescriptions or administrations in the year preceding COVID-19, not including corticosteroids). Codes are available through download. <a href="https://github.com/PCORnet-DRN-OC/Query-Details/tree/master/Therapeutics%20Query" class="tp-link-policy" data-domain-ext="com">https://github.com/PCORnet-DRN-OC/Query-Details/tree/master/Therapeutics%20Query<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></p> <p class="Footnote"><sup>&dagger;&dagger;&dagger;</sup> In the PCORnet common data model, Hispanic is defined as Cuban, Mexican, Puerto Rican, South or Central American or other Spanish culture or origin, regardless of race, and is compatible with the Office of Management and Budget definition of Hispanic ethnicity (Hispanic or Latino and not Hispanic or Latino). Data by race and ethnicity are presented separately because the PCORnet distributed query statistical program only allows for assessment of combined race and ethnicity during the full study period (January–July 2022) and not by month or for shorter periods (April–July 2022).</p> <p class="Footnote"><sup>§§§</sup> The presence of an underlying medical condition required at least two ICD-10-CM codes for that condition during the 3 years preceding COVID-19. A subset of underlying medical conditions that increase risk for severe COVID-19 outcomes was assessed. <a href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html">https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html</a></p> <p class="Footnote"><sup>¶¶¶</sup> 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. Sect. 3501 et seq.</p> <p class="Footnote">**** Sixty-four percent of COVID-19 patients were identified by a positive SARS-CoV-2 viral test result, 33% by a diagnostic code (without a positive viral test result), and 4% by treatment with one of four medications indicated only for treatment of COVID-19 (without a diagnostic code or a positive viral test result).</p> <p class="Footnote"><sup>&dagger;&dagger;&dagger;&dagger;</sup> Combined race and ethnicity could only be assessed during the full study period. During January–July 2022, Paxlovid treatment was 14.3% among non-Hispanic White (combined race and ethnicity) patients compared with 13.5% among White (race) patients and 12.8% among non-Hispanic (ethnicity) patients.</p> <p class="Footnote"><sup>§§§§</sup> <a href="https://www.kff.org/coronavirus-covid-19/issue-brief/how-equitable-is-access-to-covid-19-treatments" class="tp-link-policy" data-domain-ext="org">https://www.kff.org/coronavirus-covid-19/issue-brief/how-equitable-is-access-to-covid-19-treatments<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></p> <p class="Footnote"><sup>¶¶¶¶</sup> <a href="https://www.cdc.gov/vaccines/covid-19/downloads/guide-community-partners.pdf" target="_blank">https://www.cdc.gov/vaccines/covid-19/downloads/guide-community-partners.pdf<span aria-label="pdf icon" class="sr-only" role="img"></span><span class="fi cdc-icon-pdf x16 fill-pdf" alt="" aria-hidden="true"></span><span class="file-details"></span></a></p> <p class="Footnote">***** <a href="https://aspr.hhs.gov/TestToTreat/Pages/default.aspx" class="tp-link-policy" data-domain-ext="gov">https://aspr.hhs.gov/TestToTreat/Pages/default.aspx<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></p> <p class="Footnote"><sup>&dagger;&dagger;&dagger;&dagger;&dagger;</sup> <a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html</a></p> </div> </div><div class="order-4"><p class="text-right"><a href="#">Top</a></p></div><div class="order-4 w-100"><h2><a id="References" class="onThisPageAnchor" title="References"></a>References</h2> <ol> <li>Wiltz JL, Feehan AK, Molinari NM, et al. Racial and ethnic disparities in receipt of medications for treatment of COVID-19—United States, March 2020–August 2021. MMWR Morb Mortal Wkly Rep 2022;71:96–102. <a href="http://doi.org/10.15585/mmwr.mm7103e1" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="org">https://doi.org/10.15585/mmwr.mm7103e1<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a> <a href="http://www.ncbi.nlm.nih.gov/pubmed/35051133" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="gov">PMID:35051133<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></li> <li>Gold JAW, Kelleher J, Magid J, et al. Dispensing of oral antiviral drugs for treatment of COVID-19 by zip code–level social vulnerability—United States, December 23, 2021–May 21, 2022. MMWR Morb Mortal Wkly Rep 2022;71:825–9. <a href="http://doi.org/10.15585/mmwr.mm7125e1" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="org">https://doi.org/10.15585/mmwr.mm7125e1<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a> <a href="http://www.ncbi.nlm.nih.gov/pubmed/35737571" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="gov">PMID:35737571<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></li> <li>Sullivan M, Perrine CG, Kelleher J, et al. Notes from the field: dispensing of oral antiviral drugs for treatment of COVID-19 and zip code-level social vulnerability—United States, December 23, 2021–August 28, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1384–5.</li> <li>Shepherd SM, Willis-Esqueda C, Paradies Y, Sivasubramaniam D, Sherwood J, Brockie T. Racial and cultural minority experiences and perceptions of health care provision in a mid-western region. Int J Equity Health 2018;17:33. <a href="http://doi.org/10.1186/s12939-018-0744-x" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="org">https://doi.org/10.1186/s12939-018-0744-x<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a> <a href="http://www.ncbi.nlm.nih.gov/pubmed/29548328" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="gov">PMID:29548328<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></li> <li>FitzGerald C, Hurst S. Implicit bias in healthcare professionals: a systematic review. BMC Med Ethics 2017;18:19. <a href="http://doi.org/10.1186/s12910-017-0179-8" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="org">https://doi.org/10.1186/s12910-017-0179-8<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a> <a href="http://www.ncbi.nlm.nih.gov/pubmed/28249596" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="gov">PMID:28249596<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></li> <li>Rivera V, Aldridge MD, Ornstein K, Moody KA, Chun A. Racial and socioeconomic disparities in access to telehealth. J Am Geriatr Soc 2021;69:44–5. <a href="http://doi.org/10.1111/jgs.16904" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="org">https://doi.org/10.1111/jgs.16904<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a> <a href="http://www.ncbi.nlm.nih.gov/pubmed/33075143" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="gov">PMID:33075143<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></li> <li>Wu EL, Kumar RN, Moore WJ, et al. Disparities in COVID-19 monoclonal antibody delivery: a retrospective cohort study. J Gen Intern Med 2022;37:2505–13. <a href="http://doi.org/10.1007/s11606-022-07603-4" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="org">https://doi.org/10.1007/s11606-022-07603-4<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a> <a href="http://www.ncbi.nlm.nih.gov/pubmed/35469360" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="gov">PMID:35469360<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></li> <li>Chhibber A, Kharat A, Duong K, et al. Strategies to minimize inequity in COVID-19 vaccine access in the US: implications for future vaccine rollouts. Lancet Reg Health Am 2022;7:100138. <a href="http://doi.org/10.1016/j.lana.2021.100138" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="org">https://doi.org/10.1016/j.lana.2021.100138<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a> <a href="http://www.ncbi.nlm.nih.gov/pubmed/34901919" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="gov">PMID:34901919<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></li> <li>Mayfield CA, Sparling A, Hardeman G, et al. Development, implementation, and results from a COVID-19 messaging campaign to promote health care seeking behaviors among community clinic patients. J Community Health 2021;46:728–39. <a href="http://doi.org/10.1007/s10900-020-00939-0" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="org">https://doi.org/10.1007/s10900-020-00939-0<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a> <a href="http://www.ncbi.nlm.nih.gov/pubmed/33128160" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="gov">PMID:33128160<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></li> <li>Massetti GM, Jackson BR, Brooks JT, et al. Summary of guidance for minimizing the impact of COVID-19 on individual persons, communities, and health care systems—United States, August 2022. MMWR Morb Mortal Wkly Rep 2022;71:1057–64. <a href="http://doi.org/10.15585/mmwr.mm7133e1" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="org">https://doi.org/10.15585/mmwr.mm7133e1<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a> <a href="http://www.ncbi.nlm.nih.gov/pubmed/35980866" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="gov">PMID:35980866<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a></li> </ol> </div><div class="order-4"><p class="text-right"><a href="#">Top</a></p></div><div class="order-4 w-100"><table class="table table-bordered table-responsive"> <caption class="caption-top h4 text-black" style="text-align: left"><a id="T1_down"></a> <h5><strong>TABLE 1. Demographic and clinical characteristics of patients with COVID-19* and those treated with four outpatient medications<sup>&dagger;</sup> and the percentage of COVID-19 patients treated with each medication among adults aged ≥20 years ― PCORnet, the National Patient-Centered Clinical Research Network, 30 U.S. sites, January–July 2022</strong><a href="#T1_up"><img loading="lazy" decoding="async" class="float-right" title="Return to your place in the text" src="//www.cdc.gov/images/arrow_up.gif" alt="Return to your place in the text" width="58" height="34" border="0"></a></h5> </caption> <thead> <tr> <th class="row1left" rowspan="3" scope="col" align="left" valign="bottom">Characteristic</th> <th class="row1" colspan="5" scope="col" align="center" valign="bottom">No. (column %)</th> <th class="row1" colspan="4" rowspan="2" scope="col" align="center" valign="bottom">% of COVID-19 patients treated (row %), by medication type<sup>§</sup></th> </tr> <tr> <th class="row1" colspan="1" rowspan="2" scope="col" align="center" valign="bottom">Patients with COVID-19</th> <th class="row1" colspan="4" scope="col" align="center" valign="bottom">COVID-19 patients treated, by medication type</th> </tr> <tr> <th class="row1" colspan="1" scope="col" align="center" valign="bottom">Paxlovid</th> <th class="row1" scope="col" align="center" valign="bottom">mAbs</th> <th class="row1" scope="col" align="center" valign="bottom">Lagevrio</th> <th class="row1" scope="col" align="center" valign="bottom">Veklury</th> <th class="row1" scope="col" align="center" valign="bottom">Paxlovid</th> <th class="row1" scope="col" align="center" valign="bottom">mAbs</th> <th class="row1" scope="col" align="center" valign="bottom">Lagevrio</th> <th class="row1" scope="col" align="center" valign="bottom">Veklury</th> </tr> </thead> <tbody> <tr> <td align="left" valign="top"><b><b>Total</b></b></td> <td align="center" valign="top"><strong>692,570 (100)</strong></td> <td align="center" valign="top"><strong>81,373 (100)</strong></td> <td align="center" valign="top"><strong>18,949 (100)</strong></td> <td align="center" valign="top"><strong>7,262 (100)</strong></td> <td align="center" valign="top"><strong>4,721 (100)</strong></td> <td align="center" valign="top"><strong>11.7</strong></td> <td align="center" valign="top"><strong>2.7</strong></td> <td align="center" valign="top"><strong>1.0</strong></td> <td align="center" valign="top"><strong>0.7</strong></td> </tr> <tr> <td colspan="10" align="left" valign="top"><b><b>Age group, yrs</b></b></td> </tr> <tr> <td align="left" valign="top">20–49</td> <td align="center" valign="top">366,552 (52.9)</td> <td align="center" valign="top">26,290 (32.3)</td> <td align="center" valign="top">5,008 (26.4)</td> <td align="center" valign="top">1,775 (24.4)</td> <td align="center" valign="top">835 (17.7)</td> <td align="center" valign="top">7.2</td> <td align="center" valign="top">1.4</td> <td align="center" valign="top">0.5</td> <td align="center" valign="top">0.2</td> </tr> <tr> <td align="left" valign="top">50–64</td> <td align="center" valign="top">172,654 (24.9)</td> <td align="center" valign="top">24,825 (30.5)</td> <td align="center" valign="top">5,028 (26.5)</td> <td align="center" valign="top">2,188 (30.1)</td> <td align="center" valign="top">1,227 (26.0)</td> <td align="center" valign="top">14.4</td> <td align="center" valign="top">2.9</td> <td align="center" valign="top">1.3</td> <td align="center" valign="top">0.7</td> </tr> <tr> <td align="left" valign="top">65–79</td> <td align="center" valign="top">118,109 (17.1)</td> <td align="center" valign="top">24,645 (30.3)</td> <td align="center" valign="top">6,568 (34.7)</td> <td align="center" valign="top">2,560 (35.3)</td> <td align="center" valign="top">1,685 (35.7)</td> <td align="center" valign="top">20.9</td> <td align="center" valign="top">5.6</td> <td align="center" valign="top">2.2</td> <td align="center" valign="top">1.4</td> </tr> <tr> <td align="left" valign="top">≥80</td> <td align="center" valign="top">35,255 (5.1)</td> <td align="center" valign="top">5,608 (6.9)</td> <td align="center" valign="top">2,345 (12.4)</td> <td align="center" valign="top">739 (10.2)</td> <td align="center" valign="top">974 (20.6)</td> <td align="center" valign="top">15.9</td> <td align="center" valign="top">6.7</td> <td align="center" valign="top">2.1</td> <td align="center" valign="top">2.8</td> </tr> <tr> <td align="left" valign="top">Missing</td> <td align="center" valign="top">0 (—)</td> <td align="center" valign="top">5 (0)</td> <td align="center" valign="top">0 (—)</td> <td align="center" valign="top">0 (—)</td> <td align="center" valign="top">0 (—)</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">NC</td> </tr> <tr> <td colspan="10" align="left" valign="top"><b><b>Sex</b></b></td> </tr> <tr> <td align="left" valign="top">Male</td> <td align="center" valign="top">273,401 (39.5)</td> <td align="center" valign="top">32,596 (40.1)</td> <td align="center" valign="top">8,085 (42.7)</td> <td align="center" valign="top">3,122 (43.0)</td> <td align="center" valign="top">2,445 (51.8)</td> <td align="center" valign="top">11.9</td> <td align="center" valign="top">3.0</td> <td align="center" valign="top">1.1</td> <td align="center" valign="top">0.9</td> </tr> <tr> <td align="left" valign="top">Female</td> <td align="center" valign="top">418,911 (60.5)</td> <td align="center" valign="top">48,764 (59.9)</td> <td align="center" valign="top">10,861 (57.3)</td> <td align="center" valign="top">4,140 (57.0)</td> <td align="center" valign="top">2,276 (48.2)</td> <td align="center" valign="top">11.6</td> <td align="center" valign="top">2.6</td> <td align="center" valign="top">1.0</td> <td align="center" valign="top">0.5</td> </tr> <tr> <td align="left" valign="top">Missing</td> <td align="center" valign="top">253 (0)</td> <td align="center" valign="top">13 (0)</td> <td align="center" valign="top">1 (0)</td> <td align="center" valign="top">0 (—)</td> <td align="center" valign="top">0 (—)</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">NC</td> </tr> <tr> <td colspan="10" align="left" valign="top"><b><b>Race</b></b></td> </tr> <tr> <td align="left" valign="top">AIAN/NHOPI<sup>¶</sup></td> <td align="center" valign="top">7,631 (1.1)</td> <td align="center" valign="top">606 (0.7)</td> <td align="center" valign="top">120 (0.6)</td> <td align="center" valign="top">25 (0.3)</td> <td align="center" valign="top">27 (0.6)</td> <td align="center" valign="top">7.9</td> <td align="center" valign="top">1.6</td> <td align="center" valign="top">0.3</td> <td align="center" valign="top">0.4</td> </tr> <tr> <td align="left" valign="top">Asian</td> <td align="center" valign="top">27,673 (4.0)</td> <td align="center" valign="top">3,287 (4.0)</td> <td align="center" valign="top">458 (2.4)</td> <td align="center" valign="top">149 (2.1)</td> <td align="center" valign="top">125 (2.6)</td> <td align="center" valign="top">11.9</td> <td align="center" valign="top">1.7</td> <td align="center" valign="top">0.5</td> <td align="center" valign="top">0.5</td> </tr> <tr> <td align="left" valign="top">Black</td> <td align="center" valign="top">95,792 (13.8)</td> <td align="center" valign="top">6,714 (8.3)</td> <td align="center" valign="top">1,914 (10.1)</td> <td align="center" valign="top">860 (11.8)</td> <td align="center" valign="top">1,027 (21.8)</td> <td align="center" valign="top">7.0</td> <td align="center" valign="top">2.0</td> <td align="center" valign="top">0.9</td> <td align="center" valign="top">1.1</td> </tr> <tr> <td align="left" valign="top">White</td> <td align="center" valign="top">472,329 (68.2)</td> <td align="center" valign="top">63,715 (78.3)</td> <td align="center" valign="top">15,373 (81.1)</td> <td align="center" valign="top">5,682 (78.2)</td> <td align="center" valign="top">3,072 (65.1)</td> <td align="center" valign="top">13.5</td> <td align="center" valign="top">3.3</td> <td align="center" valign="top">1.2</td> <td align="center" valign="top">0.7</td> </tr> <tr> <td align="left" valign="top">Multiple or other**</td> <td align="center" valign="top">38,447 (5.6)</td> <td align="center" valign="top">3,250 (4.0)</td> <td align="center" valign="top">674 (3.6)</td> <td align="center" valign="top">220 (3.0)</td> <td align="center" valign="top">27 (0.6)</td> <td align="center" valign="top">8.5</td> <td align="center" valign="top">1.8</td> <td align="center" valign="top">0.6</td> <td align="center" valign="top">0.8</td> </tr> <tr> <td align="left" valign="top">Missing</td> <td align="center" valign="top">50,698 (7.3)</td> <td align="center" valign="top">3,790 (4.7)</td> <td align="center" valign="top">405 (2.1)</td> <td align="center" valign="top">326 (4.5)</td> <td align="center" valign="top">303 (6.4)</td> <td align="center" valign="top">5.1</td> <td align="center" valign="top">0.8</td> <td align="center" valign="top">0.6</td> <td align="center" valign="top">0.3</td> </tr> <tr> <td colspan="10" align="left" valign="top"><b><b>Ethnicity</b></b></td> </tr> <tr> <td align="left" valign="top">Hispanic</td> <td align="center" valign="top">81,609 (11.8)</td> <td align="center" valign="top">5,390 (6.6)</td> <td align="center" valign="top">914 (4.8)</td> <td align="center" valign="top">314 (4.3)</td> <td align="center" valign="top">418 (8.9)</td> <td align="center" valign="top">6.6</td> <td align="center" valign="top">1.1</td> <td align="center" valign="top">0.4</td> <td align="center" valign="top">0.5</td> </tr> <tr> <td align="left" valign="top">Non-Hispanic</td> <td align="center" valign="top">551,052 (79.6)</td> <td align="center" valign="top">70,537 (86.7)</td> <td align="center" valign="top">17,299 (91.3)</td> <td align="center" valign="top">6,491 (89.4)</td> <td align="center" valign="top">4,178 (88.5)</td> <td align="center" valign="top">12.8</td> <td align="center" valign="top">3.1</td> <td align="center" valign="top">1.2</td> <td align="center" valign="top">0.8</td> </tr> <tr> <td align="left" valign="top">Missing</td> <td align="center" valign="top">59,909 (8.7)</td> <td align="center" valign="top">5,443 (6.7)</td> <td align="center" valign="top">736 (3.9)</td> <td align="center" valign="top">457 (6.3)</td> <td align="center" valign="top">125 (2.6)</td> <td align="center" valign="top">9.1</td> <td align="center" valign="top">1.2</td> <td align="center" valign="top">0.8</td> <td align="center" valign="top">0.2</td> </tr> <tr> <td colspan="10" align="left" valign="top"><b><b>Immunocompromise</b></b><sup>&dagger;&dagger;,§§</sup></td> </tr> <tr> <td align="left" valign="top">Previous organ transplant</td> <td align="center" valign="top">9,457 (1.4)</td> <td align="center" valign="top">406 (0.5)</td> <td align="center" valign="top">2,025 (10.7)</td> <td align="center" valign="top">453 (6.2)</td> <td align="center" valign="top">411 (8.7)</td> <td align="center" valign="top">4.3</td> <td align="center" valign="top">21.4</td> <td align="center" valign="top">4.8</td> <td align="center" valign="top">4.3</td> </tr> <tr> <td align="left" valign="top">Active cancer treatment</td> <td align="center" valign="top">17,967 (2.6)</td> <td align="center" valign="top">2,917 (3.6)</td> <td align="center" valign="top">2,255 (11.9)</td> <td align="center" valign="top">328 (4.5)</td> <td align="center" valign="top">548 (11.6)</td> <td align="center" valign="top">16.2</td> <td align="center" valign="top">12.6</td> <td align="center" valign="top">1.8</td> <td align="center" valign="top">3.1</td> </tr> <tr> <td align="left" valign="top">Corticosteroid use</td> <td align="center" valign="top">35,737 (5.2)</td> <td align="center" valign="top">5,139 (6.3)</td> <td align="center" valign="top">3,078 (16.2)</td> <td align="center" valign="top">857 (11.8)</td> <td align="center" valign="top">1,059 (22.4)</td> <td align="center" valign="top">14.4</td> <td align="center" valign="top">8.6</td> <td align="center" valign="top">2.4</td> <td align="center" valign="top">3.0</td> </tr> <tr> <td align="left" valign="top">Immunosuppressive medication use</td> <td align="center" valign="top">23,538 (3.4)</td> <td align="center" valign="top">3,904 (4.8)</td> <td align="center" valign="top">3,572 (18.9)</td> <td align="center" valign="top">788 (10.9)</td> <td align="center" valign="top">693 (14.7)</td> <td align="center" valign="top">16.6</td> <td align="center" valign="top">15.2</td> <td align="center" valign="top">3.3</td> <td align="center" valign="top">2.9</td> </tr> <tr> <td colspan="10" align="left" valign="top"><b><b>Underlying medical condition</b></b><sup>§§,¶¶</sup></td> </tr> <tr> <td align="left" valign="top">Asthma</td> <td align="center" valign="top">49,780 (7.2)</td> <td align="center" valign="top">8,309 (10.2)</td> <td align="center" valign="top">26 (0.1)</td> <td align="center" valign="top">819 (11.3)</td> <td align="center" valign="top">364 (7.7)</td> <td align="center" valign="top">16.7</td> <td align="center" valign="top">0.1</td> <td align="center" valign="top">1.6</td> <td align="center" valign="top">0.7</td> </tr> <tr> <td align="left" valign="top">Autism</td> <td align="center" valign="top">961 (0.1)</td> <td align="center" valign="top">124 (0.2)</td> <td align="center" valign="top">26 (0.1)</td> <td align="center" valign="top">15 (0.2)</td> <td align="center" valign="top">5 (0.1)</td> <td align="center" valign="top">12.9</td> <td align="center" valign="top">2.7</td> <td align="center" valign="top">1.6</td> <td align="center" valign="top">0.5</td> </tr> <tr> <td align="left" valign="top">Cancer</td> <td align="center" valign="top">39,868 (5.8)</td> <td align="center" valign="top">7,484 (9.2)</td> <td align="center" valign="top">3,742 (19.7)</td> <td align="center" valign="top">783 (10.8)</td> <td align="center" valign="top">799 (16.9)</td> <td align="center" valign="top">18.8</td> <td align="center" valign="top">9.4</td> <td align="center" valign="top">2.0</td> <td align="center" valign="top">2.0</td> </tr> <tr> <td align="left" valign="top">Chronic kidney disease</td> <td align="center" valign="top">33,512 (4.8)</td> <td align="center" valign="top">3,319 (4.1)</td> <td align="center" valign="top">3,067 (16.2)</td> <td align="center" valign="top">890 (12.3)</td> <td align="center" valign="top">930 (19.7)</td> <td align="center" valign="top">9.9</td> <td align="center" valign="top">9.2</td> <td align="center" valign="top">2.7</td> <td align="center" valign="top">2.8</td> </tr> <tr> <td align="left" valign="top">Chronic obstructive pulmonary disease</td> <td align="center" valign="top">19,860 (2.9)</td> <td align="center" valign="top">2,193 (2.7)</td> <td align="center" valign="top">1,224 (6.5)</td> <td align="center" valign="top">441 (6.1)</td> <td align="center" valign="top">610 (12.9)</td> <td align="center" valign="top">11.0</td> <td align="center" valign="top">6.2</td> <td align="center" valign="top">2.2</td> <td align="center" valign="top">3.1</td> </tr> <tr> <td align="left" valign="top">Chronic pulmonary disorder</td> <td align="center" valign="top">75,574 (10.9)</td> <td align="center" valign="top">11,532 (14.2)</td> <td align="center" valign="top">3,714 (19.6)</td> <td align="center" valign="top">1,384 (19.1)</td> <td align="center" valign="top">1,027 (21.8)</td> <td align="center" valign="top">15.3</td> <td align="center" valign="top">4.9</td> <td align="center" valign="top">1.8</td> <td align="center" valign="top">1.4</td> </tr> <tr> <td align="left" valign="top">Cirrhosis</td> <td align="center" valign="top">4,591 (0.7)</td> <td align="center" valign="top">417 (0.5)</td> <td align="center" valign="top">402 (2.1)</td> <td align="center" valign="top">104 (1.4)</td> <td align="center" valign="top">112 (2.4)</td> <td align="center" valign="top">9.1</td> <td align="center" valign="top">8.8</td> <td align="center" valign="top">2.3</td> <td align="center" valign="top">2.4</td> </tr> <tr> <td align="left" valign="top">Congestive heart failure</td> <td align="center" valign="top">27,345 (3.9)</td> <td align="center" valign="top">2,530 (3.1)</td> <td align="center" valign="top">2,117 (11.2)</td> <td align="center" valign="top">652 (9.0)</td> <td align="center" valign="top">967 (20.5)</td> <td align="center" valign="top">9.3</td> <td align="center" valign="top">7.7</td> <td align="center" valign="top">2.4</td> <td align="center" valign="top">3.5</td> </tr> <tr> <td align="left" valign="top">Coronary artery disease</td> <td align="center" valign="top">40,249 (5.8)</td> <td align="center" valign="top">6,176 (7.6)</td> <td align="center" valign="top">3,201 (16.9)</td> <td align="center" valign="top">1,009 (13.9)</td> <td align="center" valign="top">963 (20.4)</td> <td align="center" valign="top">15.3</td> <td align="center" valign="top">8.8</td> <td align="center" valign="top">2.5</td> <td align="center" valign="top">2.4</td> </tr> <tr> <td align="left" valign="top">Cystic fibrosis</td> <td align="center" valign="top">533 (0.1)</td> <td align="center" valign="top">148 (0.2)</td> <td align="center" valign="top">69 (0.4)</td> <td align="center" valign="top">27 (0.4)</td> <td align="center" valign="top">9 (0.2)</td> <td align="center" valign="top">27.8</td> <td align="center" valign="top">12.9</td> <td align="center" valign="top">5.1</td> <td align="center" valign="top">1.7</td> </tr> <tr> <td align="left" valign="top">Dementia</td> <td align="center" valign="top">6,687 (1.0)</td> <td align="center" valign="top">598 (0.7)</td> <td align="center" valign="top">339 (1.8)</td> <td align="center" valign="top">125 (1.7)</td> <td align="center" valign="top">285 (6.0)</td> <td align="center" valign="top">8.9</td> <td align="center" valign="top">5.1</td> <td align="center" valign="top">1.9</td> <td align="center" valign="top">4.3</td> </tr> <tr> <td align="left" valign="top">Diabetes, type 1</td> <td align="center" valign="top">5,102 (0.7)</td> <td align="center" valign="top">852 (1.0)</td> <td align="center" valign="top">356 (1.9)</td> <td align="center" valign="top">101 (1.4)</td> <td align="center" valign="top">66 (1.4)</td> <td align="center" valign="top">16.7</td> <td align="center" valign="top">7.0</td> <td align="center" valign="top">2.0</td> <td align="center" valign="top">1.3</td> </tr> <tr> <td align="left" valign="top">Diabetes, type 2</td> <td align="center" valign="top">76,372 (11.0)</td> <td align="center" valign="top">10,984 (13.5)</td> <td align="center" valign="top">4,235 (22.3)</td> <td align="center" valign="top">1,475 (20.3)</td> <td align="center" valign="top">1,216 (25.8)</td> <td align="center" valign="top">14.4</td> <td align="center" valign="top">5.5</td> <td align="center" valign="top">1.9</td> <td align="center" valign="top">1.6</td> </tr> <tr> <td align="left" valign="top">Down syndrome</td> <td align="center" valign="top">319 (0)</td> <td align="center" valign="top">63 (0.1)</td> <td align="center" valign="top">15 (0.1)</td> <td align="center" valign="top">2 (0)</td> <td align="center" valign="top">5 (0.1)</td> <td align="center" valign="top">19.7</td> <td align="center" valign="top">4.7</td> <td align="center" valign="top">0.6</td> <td align="center" valign="top">1.6</td> </tr> <tr> <td align="left" valign="top">Hemiplegia</td> <td align="center" valign="top">2,692 (0.4)</td> <td align="center" valign="top">274 (0.3)</td> <td align="center" valign="top">134 (0.7)</td> <td align="center" valign="top">45 (0.6)</td> <td align="center" valign="top">82 (1.7)</td> <td align="center" valign="top">10.2</td> <td align="center" valign="top">5.0</td> <td align="center" valign="top">1.7</td> <td align="center" valign="top">3.0</td> </tr> <tr> <td align="left" valign="top">HIV</td> <td align="center" valign="top">4,201 (0.6)</td> <td align="center" valign="top">626 (0.8)</td> <td align="center" valign="top">140 (0.7)</td> <td align="center" valign="top">53 (0.7)</td> <td align="center" valign="top">49 (1.0)</td> <td align="center" valign="top">14.9</td> <td align="center" valign="top">3.3</td> <td align="center" valign="top">1.3</td> <td align="center" valign="top">1.2</td> </tr> <tr> <td align="left" valign="top">Mental health disorder</td> <td align="center" valign="top">79,080 (11.4)</td> <td align="center" valign="top">10,489 (12.9)</td> <td align="center" valign="top">3,095 (16.3)</td> <td align="center" valign="top">1,110 (15.3)</td> <td align="center" valign="top">621 (13.2)</td> <td align="center" valign="top">13.3</td> <td align="center" valign="top">3.9</td> <td align="center" valign="top">1.4</td> <td align="center" valign="top">0.8</td> </tr> <tr> <td align="left" valign="top">Obesity (BMI ≥30 kg/m<sup>2</sup>)</td> <td align="center" valign="top">192,559 (27.8)</td> <td align="center" valign="top">25,425 (31.2)</td> <td align="center" valign="top">6,727 (35.5)</td> <td align="center" valign="top">2,923 (40.3)</td> <td align="center" valign="top">1,816 (38.5)</td> <td align="center" valign="top">13.2</td> <td align="center" valign="top">3.5</td> <td align="center" valign="top">1.5</td> <td align="center" valign="top">0.9</td> </tr> <tr> <td align="left" valign="top">Smoking, current or former</td> <td align="center" valign="top">136,852 (19.8)</td> <td align="center" valign="top">15,926 (19.6)</td> <td align="center" valign="top">5,007 (26.4)</td> <td align="center" valign="top">2,053 (28.3)</td> <td align="center" valign="top">1,611 (34.1)</td> <td align="center" valign="top">12.2</td> <td align="center" valign="top">3.8</td> <td align="center" valign="top">1.6</td> <td align="center" valign="top">1.2</td> </tr> </tbody> </table> <p class="caption"><b><b>Abbreviations</b></b>: AIAN/NHOPI = American Indian or Alaska Native and Native Hawaiian or other Pacific Islander; BMI = body mass index; ICD-10-CM = <i><i>International Classification of Diseases, Tenth Revision, Clinical Modification;</i></i> mAbs = monoclonal antibodies; NC = not calculated.<br> * COVID-19 patients were identified by a positive SARS-CoV-2 viral test result, an ICD-10-CM diagnostic code for COVID-19 (U07.1 and U07.2), or treatment with a COVID-19 medication (Paxlovid, Lagevrio, mAbs, or Veklury).<br> <sup>&dagger;</sup> Patients were considered treated if they were prescribed Paxlovid or Lagevrio or administered Veklury or mAbs.<br> <b><b><sup>§</sup></b></b> Receipt of any outpatient treatment was not calculated but can be estimated by summing the percentage of COVID-19 patients treated across the four medication types. This will overestimate receipt of any outpatient treatment because treatment groups were not mutually exclusive. For example, among 81,373 patients prescribed Paxlovid, 579 (0.7%) were also treated with mAbs (491 bebtelovimab), 619 (0.8%) with Lagevrio, and 203 (0.2%) with Veklury.<br> <sup>¶</sup> Among 7,631 patients of AIAN/NHOPI race, 67% were AIAN and 33% were NHOPI.<br> **Among 38,447 patients of multiple or other race, 19% were multiple race and 81% were other race. Approximately 58% of multiple and other race patients were of Hispanic ethnicity.<br> <sup>&dagger;&dagger;</sup> Patients with immunocompromise were identified as follows: previous organ transplant (one or more ICD-10-CM codes at any time preceding COVID-19); active cancer treatment (three or more ICD-10-CM codes for cancer during the 6 months preceding COVID-19); corticosteroid use (two or more prescriptions during the year preceding COVID-19); and immunosuppressive medication use (one or more prescriptions for or administrations of a noncorticosteroid immunosuppressive medication during the year preceding COVID-19).<br> <b><b><sup>§§</sup></b></b> Some conditions can result in a contraindication to Paxlovid use or require treatment with medications that have drug-drug interactions resulting in inability to use Paxlovid. <a href="https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/" class="tp-link-policy" data-domain-ext="gov">https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir–paxlovid-/paxlovid-drug-drug-interactions/<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a><br> <sup>¶¶</sup> Presence of an underlying medical condition required the presence of at least two ICD-10-CM codes for that condition during the 3 years preceding COVID-19. A subset of underlying medical conditions that increase risk for severe COVID-19 outcomes was assessed. <a href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html">https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html</a></p> </div><div class="order-4"><p class="text-right"><a href="#">Top</a></p></div><div class="order-4 w-100"><div class="col-12"></div> <h5 class="h5"><a id="F1_down"></a><a href="#F1_up"><img loading="lazy" decoding="async" class="float-right" title="Return to your place in the text" src="//www.cdc.gov/images/arrow_up.gif" alt="Return to your place in the text" width="58" height="34" border="0"></a><b>FIGURE</b>. <strong>Monthly percentage of COVID-19 patients aged ≥20 years prescribed Paxlovid,* by race and ethnicity<sup>&dagger;</sup> — PCORnet, the National Patient-Centered Clinical Research Network, 30 U.S. sites, January–July 2022</strong></h5> <div class="mb-3"><img decoding="async" class="img-fluid" alt="Figure comprises two line graphs, one by race and one by ethnicity, indicating the monthly percentage of U.S. COVID-19 patients aged ≥20 years prescribed Paxlovid during January–July 2022, based on electronic health record data from 30 sites in PCORnet, the National Patient-Centered Clinical Research Network." title="Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 ― United States, January–July 2022" src="/mmwr/volumes/71/wr/figures/mm7143a2-F-large.gif?_=92729"></div> <p><b>Abbreviations:</b> AIAN/NHOPI = American Indian or Alaska Native and Native Hawaiian or other Pacific Islander; ICD-10-CM = <i>International Classification of Diseases, Tenth Revision, Clinical Modification</i>; PCORnet = PCORnet, the National Patient-Centered Clinical Research Network.</p> <p>* COVID-19 patients were identified by a positive SARS-CoV-2 viral test result, an ICD-10-CM diagnostic code for COVID-19 (U07.1 and U07.2), or treatment with a COVID-19 medication (Paxlovid, Lagevrio, monoclonal antibodies, or Veklury). Patients were considered treated if they were prescribed Paxlovid.</p> <p><sup>&dagger;</sup> Race and ethnicity were assessed as separate variables because the PCORnet distributed query statistical program does not allow for assessment of combined race and ethnicity by month. Among 7,631 patients of AIAN/NHOPI race, 67% were AIAN and 33% were NHOPI. Among 38,447 patients of multiple or other race, 19% were multiple race and 81% were other race; 58% of multiple and other race patients were of Hispanic ethnicity.</p> </div><div class="order-4"><p class="text-right"><a href="#">Top</a></p></div><div class="order-4 w-100"><table class="table table-bordered table-responsive"> <caption class="caption-top h4 text-black" style="text-align: left"><a id="T2_down"></a> <h5><strong>TABLE 2. Absolute and relative differences in the percentage of COVID-19 patients aged ≥20 years prescribed Paxlovid,* by race, ethnicity,<sup>&dagger;</sup> and age group ― PCORnet, the National Patient-Centered Clinical Research Network, 30 U.S. sites, April–July 2022</strong><a href="#T2_up"><img loading="lazy" decoding="async" class="float-right" title="Return to your place in the text" src="//www.cdc.gov/images/arrow_up.gif" alt="Return to your place in the text" width="58" height="34" border="0"></a></h5> </caption> <tbody> <tr> <td align="left" valign="bottom"><b><b>Age group/Race and ethnicity</b></b></td> <td align="center" valign="bottom"><b><b>No. of COVID-19 patients<sup>§</sup></b></b></td> <td align="center" valign="bottom"><b><b>No. (%) treated</b></b></td> <td align="center" valign="bottom"><b><b>P-value<sup>¶</sup></b></b></td> <td align="center" valign="bottom"><b><b>Absolute difference in % treated**</b></b></td> <td align="center" valign="bottom"><b><b>Relative difference in % treated**</b></b></td> </tr> <tr> <td colspan="6" align="left" valign="bottom"><b><b>≥20 yrs</b></b></td> </tr> <tr> <td align="left" valign="top"><b><b>Total</b></b></td> <td align="center" valign="top"><strong>260,055</strong></td> <td align="center" valign="top"><strong>76,167 (29.3)</strong></td> <td align="center" valign="top"><strong>NC</strong></td> <td align="center" valign="bottom"><strong>NC</strong></td> <td align="center" valign="bottom"><strong>NC</strong></td> </tr> <tr> <td colspan="6" align="left" valign="top"><b><b>Race</b></b></td> </tr> <tr> <td align="left" valign="top">AIAN/NHOPI</td> <td align="center" valign="top">2,145</td> <td align="center" valign="top">526 (24.5)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-7.4</td> <td align="center" valign="top">-23.1</td> </tr> <tr> <td align="left" valign="top">Asian</td> <td align="center" valign="top">12,062</td> <td align="center" valign="top">3,100 (25.7)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-6.2</td> <td align="center" valign="top">-19.4</td> </tr> <tr> <td align="left" valign="top">Black</td> <td align="center" valign="top">30,482</td> <td align="center" valign="top">6,239 (20.5)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-11.4</td> <td align="center" valign="top">-35.8</td> </tr> <tr> <td align="left" valign="top">White</td> <td align="center" valign="top">187,369</td> <td align="center" valign="top">59,752 (31.9)</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">Ref</td> <td align="center" valign="top">Ref</td> </tr> <tr> <td align="left" valign="top">Multiple or other</td> <td align="center" valign="top">12,396</td> <td align="center" valign="top">2,967 (23.9)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-8.0</td> <td align="center" valign="top">-24.9</td> </tr> <tr> <td colspan="6" align="left" valign="top"><b><b>Ethnicity</b></b></td> </tr> <tr> <td align="left" valign="top">Hispanic</td> <td align="center" valign="top">23,711</td> <td align="center" valign="top">5,042 (21.3)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-9.1</td> <td align="center" valign="top">-29.9</td> </tr> <tr> <td align="left" valign="top">Non-Hispanic</td> <td align="center" valign="top">217,739</td> <td align="center" valign="top">66,043 (30.3)</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">Ref</td> <td align="center" valign="top">Ref</td> </tr> <tr> <td colspan="6" align="left" valign="top"><b><b>20–49 yrs</b></b></td> </tr> <tr> <td align="left" valign="top"><b><b>Total</b></b></td> <td align="center" valign="top"><strong>117,372</strong></td> <td align="center" valign="top"><strong>24,501 (20.9)</strong></td> <td align="center" valign="top"><strong>NC</strong></td> <td align="center" valign="top"><strong>NC</strong></td> <td align="center" valign="top"><strong>NC</strong></td> </tr> <tr> <td colspan="6" align="left" valign="top"><b><b>Race</b></b></td> </tr> <tr> <td align="left" valign="top">AIAN/NHOPI</td> <td align="center" valign="top">1,207</td> <td align="center" valign="top">254 (21.0)</td> <td align="center" valign="top">0.240</td> <td align="center" valign="top">-1.4</td> <td align="center" valign="top">-6.3</td> </tr> <tr> <td align="left" valign="top">Asian</td> <td align="center" valign="top">7,271</td> <td align="center" valign="top">1,259 (17.3)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-5.1</td> <td align="center" valign="top">-22.9</td> </tr> <tr> <td align="left" valign="top">Black</td> <td align="center" valign="top">15,632</td> <td align="center" valign="top">2,709 (17.3)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-5.1</td> <td align="center" valign="top">-22.8</td> </tr> <tr> <td align="left" valign="top">White</td> <td align="center" valign="top">77,223</td> <td align="center" valign="top">17,344 (22.5)</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">Ref</td> <td align="center" valign="top">Ref</td> </tr> <tr> <td align="left" valign="top">Multiple or other</td> <td align="center" valign="top">7,161</td> <td align="center" valign="top">1,374 (19.2)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-3.3</td> <td align="center" valign="top">-14.6</td> </tr> <tr> <td colspan="6" align="left" valign="top"><b><b>Ethnicity</b></b></td> </tr> <tr> <td align="left" valign="top">Hispanic</td> <td align="center" valign="top">14,157</td> <td align="center" valign="top">2,410 (17.0)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-4.5</td> <td align="center" valign="top">-20.8</td> </tr> <tr> <td align="left" valign="top">Non-Hispanic</td> <td align="center" valign="top">93,734</td> <td align="center" valign="top">20,145 (21.5)</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">Ref</td> <td align="center" valign="top">Ref</td> </tr> <tr> <td colspan="6" align="left" valign="top"><b><b>50–64 yrs</b></b></td> </tr> <tr> <td align="left" valign="top"><b><b>Total</b></b></td> <td align="center" valign="top"><strong>67,844</strong></td> <td align="center" valign="top"><strong>23,246 (34.3)</strong></td> <td align="center" valign="top"><strong>NC</strong></td> <td align="center" valign="top"><strong>NC</strong></td> <td align="center" valign="top"><strong>NC</strong></td> </tr> <tr> <td colspan="6" align="left" valign="top"><b><b>Race</b></b></td> </tr> <tr> <td align="left" valign="top">AIAN/NHOPI</td> <td align="center" valign="top">554</td> <td align="center" valign="top">156 (28.2)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-8.5</td> <td align="center" valign="top">-23.2</td> </tr> <tr> <td align="left" valign="top">Asian</td> <td align="center" valign="top">2,567</td> <td align="center" valign="top">890 (34.7)</td> <td align="center" valign="top">0.045</td> <td align="center" valign="top">-2.0</td> <td align="center" valign="top">-5.4</td> </tr> <tr> <td align="left" valign="top">Black</td> <td align="center" valign="top">8,724</td> <td align="center" valign="top">2,104 (24.1)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-12.5</td> <td align="center" valign="top">-34.2</td> </tr> <tr> <td align="left" valign="top">White</td> <td align="center" valign="top">49,406</td> <td align="center" valign="top">18,105 (36.6)</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">Ref</td> <td align="center" valign="top">Ref</td> </tr> <tr> <td align="left" valign="top">Multiple or other</td> <td align="center" valign="top">2,847</td> <td align="center" valign="top">863 (30.3)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-6.3</td> <td align="center" valign="top">-17.3</td> </tr> <tr> <td colspan="6" align="left" valign="top"><b><b>Ethnicity</b></b></td> </tr> <tr> <td align="left" valign="top">Hispanic</td> <td align="center" valign="top">5,940</td> <td align="center" valign="top">1,617 (27.2)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-7.9</td> <td align="center" valign="top">-22.5</td> </tr> <tr> <td align="left" valign="top">Non-Hispanic</td> <td align="center" valign="top">57,186</td> <td align="center" valign="top">20,087 (35.1)</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">Ref</td> <td align="center" valign="top">Ref</td> </tr> <tr> <td colspan="6" align="left" valign="top"><b><b>65–79 yrs</b></b></td> </tr> <tr> <td align="left" valign="top"><b><b>Total</b></b></td> <td align="center" valign="top"><strong>58,097</strong></td> <td align="center" valign="top"><strong>23,197 (39.9)</strong></td> <td align="center" valign="top"><strong>NC</strong></td> <td align="center" valign="top"><strong>NC</strong></td> <td align="center" valign="top"><strong>NC</strong></td> </tr> <tr> <td colspan="6" align="left" valign="top"><b><b>Race</b></b></td> </tr> <tr> <td align="left" valign="top">AIAN/NHOPI</td> <td align="center" valign="top">318</td> <td align="center" valign="top">96 (30.2)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-12.0</td> <td align="center" valign="top">-28.5</td> </tr> <tr> <td align="left" valign="top">Asian</td> <td align="center" valign="top">1,717</td> <td align="center" valign="top">777 (45.3)</td> <td align="center" valign="top">0.014</td> <td align="center" valign="top">3.0</td> <td align="center" valign="top">7.2</td> </tr> <tr> <td align="left" valign="top">Black</td> <td align="center" valign="top">5,024</td> <td align="center" valign="top">1,188 (23.6)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-18.6</td> <td align="center" valign="top">-44.0</td> </tr> <tr> <td align="left" valign="top">White</td> <td align="center" valign="top">46,831</td> <td align="center" valign="top">19,777 (42.2)</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">Ref</td> <td align="center" valign="top">Ref</td> </tr> <tr> <td align="left" valign="top">Multiple or other</td> <td align="center" valign="top">1,815</td> <td align="center" valign="top">591 (32.6)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-9.7</td> <td align="center" valign="top">-22.9</td> </tr> <tr> <td colspan="6" align="left" valign="top"><b><b>Ethnicity</b></b></td> </tr> <tr> <td align="left" valign="top">Hispanic</td> <td align="center" valign="top">2,830</td> <td align="center" valign="top">820 (29.0)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-11.7</td> <td align="center" valign="top">-28.8</td> </tr> <tr> <td align="left" valign="top">Non-Hispanic</td> <td align="center" valign="top">51,734</td> <td align="center" valign="top">21,050 (40.7)</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">Ref</td> <td align="center" valign="top">Ref</td> </tr> <tr> <td colspan="6" align="left" valign="top"><b><b>≥80 yrs</b></b></td> </tr> <tr> <td align="left" valign="top"><b><b>Total</b></b></td> <td align="center" valign="top"><strong>16,974</strong></td> <td align="center" valign="top"><strong>5,213 (30.7)</strong></td> <td align="center" valign="top"><strong>NC</strong></td> <td align="center" valign="top"><strong>NC</strong></td> <td align="center" valign="top"><strong>NC</strong></td> </tr> <tr> <td colspan="6" align="left" valign="top"><b><b>Race</b></b></td> </tr> <tr> <td align="left" valign="top">AIAN/NHOPI</td> <td align="center" valign="top">67</td> <td align="center" valign="top">20 (29.9)</td> <td align="center" valign="top">0.810</td> <td align="center" valign="top">-2.1</td> <td align="center" valign="top">-6.6</td> </tr> <tr> <td align="left" valign="top">Asian</td> <td align="center" valign="top">484</td> <td align="center" valign="top">174 (36.0)</td> <td align="center" valign="top">0.072</td> <td align="center" valign="top">4.0</td> <td align="center" valign="top">12.5</td> </tr> <tr> <td align="left" valign="top">Black</td> <td align="center" valign="top">1,124</td> <td align="center" valign="top">217 (19.3)</td> <td align="center" valign="top"><0.001</td> <td align="center" valign="top">-12.7</td> <td align="center" valign="top">-39.6</td> </tr> <tr> <td align="left" valign="top">White</td> <td align="center" valign="top">14,080</td> <td align="center" valign="top">4,501 (32.0)</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">Ref</td> <td align="center" valign="top">Ref</td> </tr> <tr> <td align="left" valign="top">Multiple or other</td> <td align="center" valign="top">544</td> <td align="center" valign="top">140 (25.7)</td> <td align="center" valign="top">0.003</td> <td align="center" valign="top">-6.2</td> <td align="center" valign="top">-19.5</td> </tr> <tr> <td colspan="6" align="left" valign="top"><b><b>Ethnicity</b></b></td> </tr> <tr> <td align="left" valign="top">Hispanic</td> <td align="center" valign="top">766</td> <td align="center" valign="top">195 (25.5)</td> <td align="center" valign="top">0.001</td> <td align="center" valign="top">-5.6</td> <td align="center" valign="top">-18.1</td> </tr> <tr> <td align="left" valign="top">Non-Hispanic</td> <td align="center" valign="top">15,279</td> <td align="center" valign="top">4,751 (31.1)</td> <td align="center" valign="top">NC</td> <td align="center" valign="top">Ref</td> <td align="center" valign="top">Ref</td> </tr> </tbody> </table> <p class="caption"><b><b>Abbreviations</b></b>: AIAN/NHOPI = American Indian or Alaska Native and Native Hawaiian or other Pacific Islander; ICD-10-CM = <i><i>International Classification of Diseases, Tenth Revision, Clinical Modification</i></i>; NC = not calculated; PCORnet = PCORnet, the National Patient-Centered Clinical Research Network; Ref = referent group.<br> * COVID-19 patients were identified by a positive SARS-CoV-2 viral test result, an ICD-10-CM diagnostic code for COVID-19 (U07.1 and U07.2), or treatment with a COVID-19 medication (Paxlovid, Lagevrio, monoclonal antibodies, or Veklury). Patients were considered treated if they were prescribed Paxlovid.<br> <sup>&dagger;</sup> Race and ethnicity were assessed as separate variables because the PCORnet distributed query statistical program does not allow for assessment of combined race and ethnicity by month or for shorter periods (April–July 2022). Approximately 58% of multiple and other race patients were of Hispanic ethnicity.<br> <sup>§</sup> Number of patients with missing race and missing ethnicity are not shown, but can be calculated by subtracting the number of patients with known race or ethnicity from the total number of patients.<br> <sup>¶</sup> Pearson’s chi-square tests comparing percentage treated in the minority racial and ethnic groups with percentage treated in the majority or referent group (i.e., White race and non-Hispanic ethnicity).<br> ** Absolute difference was calculated as the percentage treated in the minority racial and ethnic group minus the percentage treated in the majority or referent group (i.e., percentage point difference). Relative difference was calculated as the absolute difference divided by the percentage treated in the majority or referent group.</p> </div><div class="order-4"><p class="text-right"><a href="#">Top</a></p></div><br><div class="theme-indigo card bg-tertiary w-100 order-4"><div class="card-body"><p id="suggestedcitation" class="smallgrey"><strong>Suggested citation for this article:</strong> Boehmer TK, Koumans EH, Skillen EL, et al. Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 ― United States, January–July 2022. MMWR Morb Mortal Wkly Rep 2022;71:1359–1365. DOI: <a href="http://dx.doi.org/10.15585/mmwr.mm7143a2" target="_blank" rel="noopener noreferrer" class="tp-link-policy" data-domain-ext="org">http://dx.doi.org/10.15585/mmwr.mm7143a2<span aria-label="external icon" class="sr-only" role="img"></span><span class="fi cdc-icon-external x16 fill-external" alt="" aria-hidden="true"></span></a>.</p> </div></div><div class="pull-left order-4 w-100"><p><small> <i>MMWR</i> and <i>Morbidity and Mortality Weekly Report</i> are service marks of the U.S. Department of Health and Human Services.<br /> Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services. <br />References to non-CDC sites on the Internet are provided as a service to <i>MMWR</i> readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in <i>MMWR</i> were current as of the date of publication.</small></p> <p><small>All HTML versions of <i>MMWR</i> articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (<a href="https://www.cdc.gov/mmwr">https://www.cdc.gov/mmwr</a>) and/or the original <i>MMWR</i> paper copy for printable versions of official text, figures, and tables. </small></p> <p><small>Questions or messages regarding errors in formatting should be addressed to <a href="https://www.cdc.gov/mmwr/form/index.html">mmwrq@cdc.gov</a>.</small></div></div> </div> </div> </div> <div class="row"><div class="col page-format">View Page In:<a href="/mmwr/volumes/71/wr/pdfs/mm7143a2-H.pdf" target="_blank" rel="noopener noreferrer"><span class="icon x24"><span aria-label="pdf icon" class="sr-only" role="img"></span><span class="fi cdc-icon-pdf fill-pdf" alt="" aria-hidden="true"></span></span> PDF [168K]</a></div></div> <div class="row d-none d-lg-block"> <div class="col pca"> </div> </div> <div class="row share-row last-reviewed-row"> <div class="col-md last-reviewed"> Last Reviewed: <span id="last-reviewed-date">October 27, 2022</span> <div class="d-none d-lg-block content-source">Source: <a href="//www.cdc.gov/" class="td-none">Centers for Disease Control and Prevention</a> </div> </div> <div class="col-md page-share ml-auto"> <nav id="share-nav" class="page-share-wrapper" role="navigation" aria-label="Social Media"> <ul> <li><a target="_blank" title="Share to Facebook" rel="noreferrer noopener" class="page-share-facebook metrics-share-facebook" href="https://api.addthis.com/oexchange/0.8/forward/facebook/offer?url=https%3A%2F%2Fwww.cdc.gov%2Findex.htm&title=CDC%20Works%2024/7&description=As%20the%20nation%27s%20health%20protection%20agency,%20CDC%20saves%20lives%20and%20protects%20people%20from%20health,%20safety,%20and%20security%20threats.&via=CDCgov&ct=0&media=https://www.cdc.gov/homepage/images/centers-for-disease-control-and-prevention.png"><span class="sr-only">Facebook</span><span class="fi cdc-icon-fb-round"></span></a></li> <li><a target="_blank" title="Share to Twitter" rel="noreferrer noopener" class="page-share-twitter metrics-share-twitter" href="https://api.addthis.com/oexchange/0.8/forward/twitter/offer?url=https%3A%2F%2Fwww.cdc.gov%2Findex.htm&title=CDC%20Works%2024/7&description=As%20the%20nation%27s%20health%20protection%20agency,%20CDC%20saves%20lives%20and%20protects%20people%20from%20health,%20safety,%20and%20security%20threats.&via=CDCgov&ct=0&media=https://www.cdc.gov/homepage/images/centers-for-disease-control-and-prevention.png"><span class="sr-only">Twitter</span><span class="fi cdc-icon-twitter-round"></span></a></li> <li><a target="_blank" title="Share to LinkedIn" rel="noreferrer noopener" class="page-share-linkedin metrics-share-linkedin" href="https://api.addthis.com/oexchange/0.8/forward/linkedin/offer?url=https%3A%2F%2Fwww.cdc.gov%2Findex.htm&title=CDC%20Works%2024/7&description=As%20the%20nation%27s%20health%20protection%20agency,%20CDC%20saves%20lives%20and%20protects%20people%20from%20health,%20safety,%20and%20security%20threats.&via=CDCgov&ct=0&media=https://www.cdc.gov/homepage/images/centers-for-disease-control-and-prevention.png"><span class="sr-only">LinkedIn</span><span class="fi cdc-icon-linkedin-round"></span></a></li> <li><a target="_blank" title="Embed this Page" rel="noreferrer noopener" class="page-share-syndication metrics-share-syndicate" href="https://tools.cdc.gov/medialibrary/index.aspx#/sharecontent/https%3A%2F%2Fwww.cdc.gov%2Findex.htm"><span class="sr-only">Syndicate</span><span class="fi cdc-icon-syndication-round"></span></a></li> </ul> </nav> </div> </div> </main> <div class="col-12 d-lg-none leftnav-wrapper"> <nav role="navigation" aria-label="Left Navigation Menu"> <div id="cdc-left-nav-menu" data-menu-id="455"><ul class="list-group tp-nav-main"><li class="list-group-item nav-lvl1"><a href="/mmwr/index.html">MMWR</a></li><li class="list-group-item nav-lvl1"><a href="/mmwr/mmwr_additional_resources.html">Reports by Topic</a></li><li class="list-group-item nav-lvl1"><a href="/mmwr/publications/index.html">Publications</a><a href="#nav-group-b5a24" class="nav-plus nav-expandcollapse" data-toggle="collapse" aria-controls="nav-group-b5a24"><span class="sr-only">plus icon</span><span class="fi cdc-icon-plus" aria-hidden="true"></span></a><ul id="nav-group-b5a24" class="collapse"><li class="list-group-item nav-lvl2"><a href="/mmwr/index2024.html">Weekly Report</a><a href="#nav-group-1f8ba" class="nav-plus nav-expandcollapse" data-toggle="collapse" aria-controls="nav-group-1f8ba"><span class="sr-only">plus icon</span><span class="fi cdc-icon-plus" aria-hidden="true"></span></a><ul id="nav-group-1f8ba" class="collapse"><li class="list-group-item nav-lvl3"><a href="/mmwr/mmwr_wk/wk_pvol.html">Past Volumes (1982-2023)</a></li></ul></li><li class="list-group-item nav-lvl2"><a href="/mmwr/indrr_2024.html">Recommendations and Reports</a><a href="#nav-group-5ed3d" class="nav-plus nav-expandcollapse" data-toggle="collapse" aria-controls="nav-group-5ed3d"><span class="sr-only">plus icon</span><span class="fi cdc-icon-plus" aria-hidden="true"></span></a><ul id="nav-group-5ed3d" class="collapse"><li class="list-group-item nav-lvl3"><a href="/mmwr/mmwr_rr/rr_pvol.html">Past Volumes (1990-2022)</a></li></ul></li><li class="list-group-item nav-lvl2"><a href="/mmwr/indss_2024.html">Surveillance Summaries</a><a href="#nav-group-5cc66" class="nav-plus nav-expandcollapse" data-toggle="collapse" aria-controls="nav-group-5cc66"><span class="sr-only">plus icon</span><span class="fi cdc-icon-plus" aria-hidden="true"></span></a><ul id="nav-group-5cc66" class="collapse"><li class="list-group-item nav-lvl3"><a href="/mmwr/mmwr_ss/ss_pvol.html">Past Volumes (1983-2023)</a></li></ul></li><li class="list-group-item nav-lvl2"><a href="/mmwr/ind2024_su.html">Supplements</a><a href="#nav-group-799d5" class="nav-plus nav-expandcollapse" data-toggle="collapse" aria-controls="nav-group-799d5"><span class="sr-only">plus icon</span><span class="fi cdc-icon-plus" aria-hidden="true"></span></a><ul id="nav-group-799d5" class="collapse"><li class="list-group-item nav-lvl3"><a href="/mmwr/mmwr_su/index.html">Past Volumes (1985-2023)</a></li></ul></li><li class="list-group-item nav-lvl2"><a href="https://stacks.cdc.gov/cbrowse/?parentId=cdc:101&pid=cdc:101">Archive (1952-1981)</a></li><li class="list-group-item nav-lvl2"><a href="/mmwr/mmwr_nd/index.html">Notifiable Infectious Diseases</a></li><li class="list-group-item nav-lvl2"><a href="/mmwr/mmwr_nnc/index.html">Notifiable Noninfectious Conditions</a></li></ul></li><li class="list-group-item nav-lvl1"><a href="https://www.cdc.gov/vitalsigns/index.html">Vital Signs</a></li><li class="list-group-item nav-lvl1"><a href="/mmwr/va-search/visualAbstract.htm?Sort=Date%3A%3Adesc">Visual Abstracts</a></li><li class="list-group-item nav-lvl1"><a href="/mmwr/mmwrpodcasts.html">Podcasts</a></li><li class="list-group-item nav-lvl1"><a href="/mmwr/cme/medscape_cme.html">Continuing Education</a></li><li class="list-group-item nav-lvl1"><a href="/mmwr/newsletter/cmo/index2024.html">MMWR Clinical Pearls</a></li><li class="list-group-item nav-lvl1"><a href="/mmwr/mmwr_trends-widget.html">Metrics</a></li><li class="list-group-item nav-lvl1"><a href="/mmwr/contributors/index.html">For Authors</a></li><li class="list-group-item nav-lvl1"><a href="/mmwr/about.html">About  </a><a href="#nav-group-d3f5f" class="nav-plus nav-expandcollapse" data-toggle="collapse" aria-controls="nav-group-d3f5f"><span class="sr-only">plus icon</span><span class="fi cdc-icon-plus" aria-hidden="true"></span></a><ul id="nav-group-d3f5f" class="collapse"><li class="list-group-item nav-lvl2"><a href="/mmwr/staff/staff.html">Staff</a></li><li class="list-group-item nav-lvl2"><a href="/mmwr/editorial_board.html">Editorial Board</a></li></ul></li><li class="list-group-item nav-lvl1"><a href="/mmwr/mmwrsubscribe.html">Subscribe</a><a href="#nav-group-d9e83" class="nav-plus nav-expandcollapse" data-toggle="collapse" aria-controls="nav-group-d9e83"><span class="sr-only">plus icon</span><span class="fi cdc-icon-plus" aria-hidden="true"></span></a><ul id="nav-group-d9e83" class="collapse"><li class="list-group-item nav-lvl2"><a href="https://tools.cdc.gov/api/v2/resources/media/342778.rss">RSS Feed</a></li></ul></li></ul></div> </nav> <div class="col-12 mt-5"> </div> </div> </div> <footer class="" role="contentinfo" aria-label="Footer"> <div class="container-fluid footer-wrapper"> <div class="container"> <div class="footer-2022"> <div class="footer-desktop"> <div class="row"> <div class="col-6 about"> <ul class="d-flex"> <li><a href="https://www.cdc.gov/about/default.htm">About CDC</a></li> <li><a href="https://www.cdc.gov/cdc-info/index.html">Contact Us</a></li> <li><a href="tel:8002324636">800-232-4636</a></li> </ul> </div> <div class="col-6 social"> <div class="d-flex flex-nowrap"> <a href="https://www.facebook.com/CDC" target="_blank" rel="noreferrer noopener"><span class="cdc-icon-facebook-inverse"></span><span class="sr-only">Facebook</span></a> <a href="https://twitter.com/CDCgov" target="_blank" rel="noreferrer noopener"><span class="cdc-icon-twitter-inverse"></span><span class="sr-only">Twitter</span></a> <a href="https://www.instagram.com/CDCgov/" target="_blank" rel="noreferrer noopener"><span class="cdc-icon-instagram-inverse"></span><span class="sr-only">Instagram</span></a> <a href="https://www.linkedin.com/company/centers-for-disease-control-and-prevention" target="_blank" rel="noreferrer noopener"><span class="cdc-icon-linkedin-inverse"></span><span class="sr-only">LinkedIn</span></a> <a href="https://www.youtube.com/c/cdc/" target="_blank" rel="noreferrer noopener"><span class="cdc-icon-youtube-inverse"></span><span class="sr-only">Youtube</span></a> <a href="https://www.pinterest.com/cdcgov/" target="_blank" rel="noreferrer noopener"><span class="cdc-icon-pinterest-inverse"></span><span class="sr-only">Pinterest</span></a> <a href="https://www.snapchat.com/add/cdcgov" target="_blank" rel="noreferrer noopener"><span class="cdc-icon-snapchat-inverse"></span><span class="sr-only">Snapchat</span></a> </div> </div> </div> </div> <div class="footer-mobile" aria-label="Footer" role="contentinfo"> <ul class="accordion indicator-arrow mb-3" role="tablist" aria-busy="true"> <li class="card footer-mobile_contact" role="presentation"> <button role="tab" class="card-header tab collapsed" data-target="#footer-mobile-collapse-1" data-toggle="collapse" aria-expanded="false" id="footer-mobile-card-1" >CONTACT CDC</button> <div class="collapse" id="footer-mobile-collapse-1" role="tabpanel" aria-hidden="true"> <div class="card-body"> <address itemscope="itemscope" itemtype="https://schema.org/Organization"> <div class="row mt-2"> <div class="col-1"> <span aria-hidden="true" class="fi cdc-icon-desktop x24"></span> </div> <div class="col"> <span class="pl-1"><a href="https://www.cdc.gov/cdc-info/index.html">Contact Us</a></span> </div> </div> <div class="row mt-2"> <div class="col-1"> <span class="fi cdc-icon-phone x24"></span> </div> <div class="col"> <span class="pl-1" itemprop="telephone">Call 800-232-4636</span> </div> </div> <div class="row mt-2"> <div class="col-1"> <span class="fi cdc-icon-email x24"></span> </div> <div class="col"> <span class="pl-1" itemprop="url"><a href="https://www.cdc.gov/cdc-info/index.html">Email Us</a></span> </div> </div> </address> </div> </div> </li> <li class="card footer-mobile_about" role="presentation"> <button role="tab" class="card-header tab collapsed " data-target="#footer-mobile-collapse-2" data-toggle="collapse" aria-expanded="false" id="footer-mobile-card-2" >ABOUT CDC</button> <div class="collapse" id="footer-mobile-collapse-2" role="tabpanel" aria-hidden="true"> <div class="card-body"> <ul> <li><a href="https://www.cdc.gov/about/default.htm">About CDC</a></li> <li><a href="https://jobs.cdc.gov">Jobs</a></li> <li><a href="https://www.cdc.gov/funding">Funding</a></li> </ul> </div> </div> </li> <li class="card footer-mobile_policies" role="presentation"> <button role="tab" class="card-header tab collapsed " data-target="#footer-mobile-collapse-3" data-toggle="collapse" aria-expanded="false" id="footer-mobile-card-3">POLICIES</button> <div class="collapse" id="footer-mobile-collapse-3" role="tabpanel" aria-hidden="true"> <div class="card-body"> <ul> <li><a href="https://www.cdc.gov/other/accessibility.html">Accessibility</a></li> <li><a href="https://www.cdc.gov/Other/disclaimer.html">External Links</a></li> <li><a href="https://www.cdc.gov/other/privacy.html">Privacy</a></li> <li><a href="https://www.cdc.gov/Other/policies.html">Policies</a></li> <li><a href="https://www.cdc.gov/oeeowe/nofearact/">No Fear Act</a></li> <li><a href="https://www.cdc.gov/od/foia">FOIA</a></li> <li><a href="https://oig.hhs.gov">OIG</a></li> <li><a href="https://www.cdc.gov/other/nondiscrimination.html">Nondiscrimination</a></li> <li><a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html">Vulnerability Disclosure Policy</a></li> <li><a href="https://stacks.cdc.gov/ ">Public Health Publications</a></li> </ul> </div> </div> </li> <li class="card footer-mobile_connect" role="presentation"> <button role="tab" class="card-header tab collapsed " data-target="#footer-mobile-collapse-4" data-toggle="collapse" aria-expanded="false" id="footer-mobile-card-4">CONNECT WITH US</button> <div class="collapse" id="footer-mobile-collapse-4" role="tabpanel" aria-hidden="true"> <div class="card-body"> <ul class="bullet-list cc-4 lsp-out row"> <div class="col-12"> <li><a href="https://www.facebook.com/CDC" target="_blank" rel="noreferrer noopener"><span class="sr-only">Facebook</span><span class="fi cdc-icon-fb-white x24" aria-hidden="true"></span></a></li> <li><a href="https://twitter.com/CDCgov" target="_blank" rel="noreferrer noopener"><span class="sr-only">Twitter</span><span class="fi cdc-icon-twitter-white x24" aria-hidden="true"></span></a></li> <li><a href="https://www.instagram.com/CDCgov/" target="_blank" rel="noreferrer noopener"><span class="sr-only">Instagram</span><span class="fi cdc-icon-ig-white x24" aria-hidden="true"></span></a></li> <li><a href="https://www.linkedin.com/company/centers-for-disease-control-and-prevention" target="_blank" rel="noreferrer noopener"><span class="sr-only">LinkedIn</span><span class="fi cdc-icon-linkedin-white x24" aria-hidden="true"></span></a></li> </div> <div class="col-12"> <li><a href="https://www.youtube.com/c/cdc/" target="_blank" rel="noreferrer noopener"><span class="sr-only">Youtube</span><span class="fi cdc-icon-youtube-white x24" aria-hidden="true"></span></a></li> <li><a href="https://www.pinterest.com/cdcgov/" target="_blank" rel="noreferrer noopener"><span class="sr-only">Pinterest</span><span class="fi cdc-icon-pinterest-white x24" aria-hidden="true"></span></a></li> <li><a href="https://www.snapchat.com/add/cdcgov" target="_blank" rel="noreferrer noopener"><span class="sr-only">Snapchat</span><span class="fi cdc-icon-snapchat x24" aria-hidden="true"></span></a></li> <li><a href="https://wwwn.cdc.gov/dcs/RequestForm.aspx"><span class="sr-only">Email</span><span class="fi cdc-icon-email x24" aria-hidden="true"></span></a></li> </div> </ul> </div> </div> </li> <li class="card footer-mobile_language" role="presentation"> <button role="tab" class="card-header tab collapsed " data-target="#footer-mobile-collapse-5" data-toggle="collapse" aria-expanded="false" id="footer-mobile-card-5">LANGUAGES</button> <div class="collapse" id="footer-mobile-collapse-5" role="tabpanel" aria-hidden="true"> <div class="card-body"> <ul class="bullet-list cc-2 lsp-out"> <li lang="es"><a href="https://www.cdc.gov/other/language-assistance.html#Spanish" title="Spanish">Español</a></li> <li lang="zh"><a href="https://www.cdc.gov/other/language-assistance.html#Chinese" title="Chinese">繁體中文</a></li> <li lang="vi"><a href="https://www.cdc.gov/other/language-assistance.html#Vietnamese" title="Vietnamese">Tiếng Việt</a></li> <li lang="ko"><a href="https://www.cdc.gov/other/language-assistance.html#Korean" title="Korean">한국어</a></li> <li lang="tl"><a href="https://www.cdc.gov/other/language-assistance.html#Tagalog" title="Tagalog">Tagalog</a></li> <li lang="ru"><a href="https://www.cdc.gov/other/language-assistance.html#Russian" title="Russian">Русский</a></li> <li lang="ar"><a href="https://www.cdc.gov/other/language-assistance.html#Arabic" title="Arabic">العربية</a></li> <li lang="ht"><a href="https://www.cdc.gov/other/language-assistance.html#Haitian" title="Haitian">Kreyòl Ayisyen</a></li> <li lang="fr"><a href="https://www.cdc.gov/other/language-assistance.html#French" title="French">Français</a></li> <li lang="pl"><a href="https://www.cdc.gov/other/language-assistance.html#Polish" title="Polish">Polski</a></li> <li lang="pt"><a href="https://www.cdc.gov/other/language-assistance.html#Portuguese" title="Portuguese">Português</a></li> <li lang="it"><a href="https://www.cdc.gov/other/language-assistance.html#Italian" title="Italian">Italiano</a></li> <li lang="de"><a href="https://www.cdc.gov/other/language-assistance.html#German" title="German">Deutsch</a></li> <li lang="ja"><a href="https://www.cdc.gov/other/language-assistance.html#Japanese" title="Japanese">日本語</a></li> <li lang="fa"><a href="https://www.cdc.gov/other/language-assistance.html#Farsi" title="Farsi">فارسی</a></li> <li lang="en"><a href="https://www.cdc.gov/other/language-assistance.html#English" title="English">English</a></li> </ul> </div> </div> </li> </ul> </div> </div> </div> </div> <div class="container-fluid agency-footer"> <div class="container"> <div class="footer-2022 footer-agency row"> <div class="col"> <ul> <li><a href="https://www.hhs.gov/">U.S. Department of Health & Human Services</a></li> <li class="d-none d-md-block"><a href="https://www.cdc.gov/other/accessibility.html">Accessibility</a></li> <li class="d-none d-md-block"><a href="https://www.cdc.gov/Other/disclaimer.html">External Links</a></li> <li class="d-none d-md-block"><a href="https://www.cdc.gov/other/privacy.html">Privacy</a></li> <li class="d-none d-md-block"><a href="https://www.cdc.gov/Other/policies.html">Policies</a></li> <li class="d-none d-md-block"><a href="https://www.cdc.gov/oeeowe/nofearact/">No Fear Act</a></li> <li class="d-none d-md-block"><a href="https://www.cdc.gov/od/foia">FOIA</a></li> <li class="d-none d-md-block"><a href="https://www.cdc.gov/other/nondiscrimination.html">Nondiscrimination</a></li> <li class="d-none d-md-block"><a href="https://oig.hhs.gov">OIG</a></li> <li class="d-none d-md-block"><a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html">Vulnerability Disclosure Policy</a></li> <li class="d-none d-md-block"><a href="https://stacks.cdc.gov/ ">Public Health Publications</a></li> <li><a href="https://www.usa.gov/">USA.gov</a></li> </ul> </div> </div> </div> </div> </footer>  <script src="/config/cdc_config.js"></script> <script>var CDC_POST={"id":"826_100864","type":"cdc_mmwr","tax":{"cdc_topics":["88f3e122-1304-415c-adff-4a35740d79c0","b74b1807-8e87-42f5-b5a4-2ed8a46a07d1","cabea278-988d-49f5-bd13-5c3fab3f3504"],"cdc_categories":["2b55e648-eaa5-4e53-9b50-833393d2da21"]}};</script> <script src="/TemplatePackage/contrib/libs/jquery/latest/jquery.min.js?_=79008"></script> <script src="/TemplatePackage/contrib/libs/bootstrap/latest/js/bootstrap.bundle.min.js?_=79008"></script>    <script src="/TemplatePackage/contrib/libs/cdc/ab/4.0.0/ab.js"></script> <script src="/TemplatePackage/4.0/assets/js/app.min.js?_=79008"></script> <svg viewBox="0 0 40 40" class="d-none"> <radialGradient id="svg_ig_1" cx="-3.0686" cy="30.0001" r="39.8188" gradientTransform="matrix(0.9138 -0.3831 0.3831 0.9138 -6.346 8.975)" gradientUnits="userSpaceOnUse"> <stop offset="0" style="stop-color:#FFDD55"/> <stop offset="0.1" style="stop-color:#FFDD55"/> <stop offset="0.5" style="stop-color:#FF543E"/> <stop offset="1" style="stop-color:#C837AB"/> </radialGradient> <circle style="fill:url(#svg_ig_1);" cx="20" cy="20" r="20"/> <radialGradient id="svg_ig_2" cx="9.873329e-02" cy="-0.6373" r="22.6462" gradientTransform="matrix(0.9909 0 0 0.9909 -0.2262 -0.2261)" gradientUnits="userSpaceOnUse"> <stop offset="0" style="stop-color:#3771C8"/> <stop offset="0.128" style="stop-color:#3771C8"/> <stop offset="1" style="stop-color:#6600FF;stop-opacity:0"/> </radialGradient> <circle style="fill:url(#svg_ig_2);" cx="20" cy="20" r="20"/> <path class="fill-w" d="M20,5.5c-4,0-4.5,0-6.1,0.1c-1.6,0.1-2.6,0.3-3.6,0.7C9.4,6.7,8.5,7.2,7.7,8C6.9,8.8,6.4,9.7,6,10.6c-0.4,0.9-0.6,2-0.7,3.6c-0.1,1.6-0.1,2.1-0.1,6.1s0,4.5,0.1,6.1C5.4,28,5.6,29,6,30c0.4,1,0.9,1.8,1.7,2.6c0.8,0.8,1.6,1.3,2.6,1.7c0.9,0.4,2,0.6,3.6,0.7c1.6,0.1,2.1,0.1,6.1,0.1c4,0,4.5,0,6.1-0.1c1.6-0.1,2.6-0.3,3.6-0.7c1-0.4,1.8-0.9,2.6-1.7c0.8-0.8,1.3-1.6,1.7-2.6c0.4-0.9,0.6-2,0.7-3.6c0.1-1.6,0.1-2.1,0.1-6.1s0-4.5-0.1-6.1c-0.1-1.6-0.3-2.6-0.7-3.6c-0.4-1-0.9-1.8-1.7-2.6c-0.8-0.8-1.6-1.3-2.6-1.7c-0.9-0.4-2-0.6-3.6-0.7C24.5,5.6,24,5.5,20,5.5L20,5.5z M18.7,8.2c0.4,0,0.8,0,1.3,0c3.9,0,4.4,0,6,0.1c1.4,0.1,2.2,0.3,2.7,0.5c0.7,0.3,1.2,0.6,1.7,1.1c0.5,0.5,0.8,1,1.1,1.7c0.2,0.5,0.4,1.3,0.5,2.7c0.1,1.6,0.1,2,0.1,6s0,4.4-0.1,6c-0.1,1.4-0.3,2.2-0.5,2.7c-0.3,0.7-0.6,1.2-1.1,1.7c-0.5,0.5-1,0.8-1.7,1.1c-0.5,0.2-1.3,0.4-2.7,0.5c-1.6,0.1-2,0.1-6,0.1c-3.9,0-4.4,0-6-0.1c-1.4-0.1-2.2-0.3-2.7-0.5c-0.7-0.3-1.2-0.6-1.7-1.1c-0.5-0.5-0.8-1-1.1-1.7C8.3,28.5,8,27.7,8,26.3c-0.1-1.6-0.1-2-0.1-6s0-4.4,0.1-6c0.1-1.4,0.3-2.2,0.5-2.7c0.3-0.7,0.6-1.2,1.1-1.7c0.5-0.5,1-0.8,1.7-1.1c0.5-0.2,1.3-0.4,2.7-0.5C15.4,8.2,15.9,8.2,18.7,8.2L18.7,8.2z M27.9,10.7c-1,0-1.8,0.8-1.8,1.8c0,1,0.8,1.8,1.8,1.8s1.8-0.8,1.8-1.8S28.9,10.7,27.9,10.7L27.9,10.7z M20,12.7c-4.2,0-7.6,3.4-7.6,7.6s3.4,7.6,7.6,7.6c4.2,0,7.6-3.4,7.6-7.6S24.2,12.7,20,12.7L20,12.7z M20,15.4c2.7,0,4.9,2.2,4.9,4.9c0,2.7-2.2,4.9-4.9,4.9c-2.7,0-4.9-2.2-4.9-4.9C15.1,17.6,17.3,15.4,20,15.4z"/> </svg> <svg id="multicolor_icons" style="display:none" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">  <symbol id="powerpoint" viewBox="0 0 40 40"> <path class="fill-ppt-1" d="M21,1.5h2.45V5.39c4.61,0,9.23,0,13.84,0A1.5,1.5,0,0,1,39,7.08c.07,8.06,0,16.13,0,24.2a5.07,5.07,0,0,1-.41,2.61,3.88,3.88,0,0,1-2.19.43c-4.32,0-8.63,0-13,0v4.32H20.76C14.18,37.43,7.59,36.33,1,35.17Q1,20.07,1,5C7.66,3.81,14.32,2.64,21,1.5Z"></path> <path class="fill-ppt-2" d="M23.44,6.68H37.69V33H23.44V29.56H33.8V27.83H23.44V25.68H33.8V23.95H23.45c0-.85,0-1.69,0-2.54a6.06,6.06,0,0,0,5.18-.51,5.91,5.91,0,0,0,2.66-4.71c-1.9,0-3.79,0-5.68,0,0-1.88,0-3.76,0-5.63L23.44,11Z"></path> <path class="fill-ppt-1" d="M26.47,9.65a6.07,6.07,0,0,1,5.68,5.66c-1.9,0-3.79,0-5.69,0C26.46,13.42,26.46,11.53,26.47,9.65Z"></path> <path class="fill-ppt-2" d="M7.93,12.91c2.34.11,5.18-.93,7.13.83,1.86,2.26,1.37,6.41-1.39,7.76a6.37,6.37,0,0,1-3.17.4q0,2.53,0,5.06l-2.57-.22C7.88,22.13,7.87,17.52,7.93,12.91Z"></path> <path class="fill-ppt-1" d="M10.49,15.24c.85,0,1.9-.19,2.48.6A3.13,3.13,0,0,1,13,18.68c-.49.89-1.61.8-2.47.91C10.47,18.14,10.48,16.69,10.49,15.24Z"></path> </symbol> <symbol id="pdf" viewBox="0 0 40 40"> <path class="fill-pdf-1" d="M32.52,1H1.45V38.68h38V7.42Z"></path> <polygon class="fill-op-2" points="39.38 7.49 32.96 7.49 32.52 1.06 39.38 7.49"></polygon> <path class="fill-pdf-2" d="M16.28,23C17,21.57,17.84,20,18.5,18.33h0l.26-.64c-.86-3.3-1.38-6-.92-7.67h0A1.19,1.19,0,0,1,19,9.31h.4c.75,0,1.11.95,1.15,1.33h0a6,6,0,0,1-.22,1.68h0a4.1,4.1,0,0,0-.25-1.71h0c-.32-.69-.62-1.1-.88-1.17h0a.85.85,0,0,0-.32.64h0a9.59,9.59,0,0,0-.12,1.47h0a16.43,16.43,0,0,0,.68,4.28h0c.08-.24.16-.48.22-.7h0l.68-2.65h0s-.15,3.07-.36,4h0c0,.2-.09.39-.14.59h0a13.5,13.5,0,0,0,3.36,5.25h0a10.46,10.46,0,0,0,1.94,1.34h0a26.93,26.93,0,0,1,3.95-.3h0a5,5,0,0,1,3,.68h0a1.2,1.2,0,0,1,.33.76h0a2.6,2.6,0,0,1-.06.44h0c0-.08,0-.47-1.19-.86h0a14,14,0,0,0-4.84-.06h0c2.46,1.2,4.85,1.79,5.61,1.44h0a1.69,1.69,0,0,0,.41-.4h0a3.92,3.92,0,0,1-.23.76h0a1.2,1.2,0,0,1-.59.4h0c-1.2.32-4.31-.42-7-2h0a57.18,57.18,0,0,0-9,2.15h0c-2.63,4.6-4.6,6.71-6.21,5.91h0l-.59-.3a.69.69,0,0,1-.22-.74h0c.19-.92,1.34-2.3,3.65-3.67h0c.24-.16,1.35-.74,1.35-.74h0s-.82.79-1,1h0c-1.84,1.51-3.2,3.41-3.17,4.14h0v.07c1.56-.23,3.91-3.41,6.93-9.31m.95.49c-.5,1-1,1.83-1.45,2.63h0a38.68,38.68,0,0,1,7.8-2.2h0c-.35-.24-.68-.5-1-.76h0a13.42,13.42,0,0,1-3.29-4.28h0a35.21,35.21,0,0,1-2.06,4.61"></path> </symbol> <symbol id="zip" viewBox="0 0 40 40"> <path class="fill-zip-1" d="M32.17,1.09H1V38.77H39V7.44Z"></path> <polygon class="fill-zip-2" points="39 7.47 32.6 7.47 32.17 1.09 39 7.47"></polygon> <rect class="fill-zip-3" height="13.48" width="0.56" x="17.75" y="1.09"></rect> <rect class="fill-zip-3" height="13.48" width="0.56" x="21.69" y="1.09"></rect> <rect class="fill-zip-3" height="1.69" width="1.78" x="18.22" y="1.09"></rect> <rect class="fill-zip-3" height="1.69" width="1.78" x="20" y="2.77"></rect> <rect class="fill-zip-3" height="1.69" width="1.78" x="18.22" y="4.46"></rect> <rect class="fill-zip-3" height="1.69" width="1.78" x="20" y="6.15"></rect> <rect class="fill-zip-3" height="1.69" width="1.78" x="18.22" y="7.83"></rect> <rect class="fill-zip-3" height="1.69" width="1.78" x="20" y="9.52"></rect> <rect class="fill-zip-3" height="1.69" width="1.78" x="18.22" y="11.19"></rect> <rect class="fill-zip-3" height="1.69" width="1.78" x="20" y="12.87"></rect> <path class="fill-zip-3" d="M22.53,14.56H17.47a1,1,0,0,0-1,1V18.4a1,1,0,0,0,1,1h.84V16.51h3.38v2.85h.84a1,1,0,0,0,1-1V15.53A1,1,0,0,0,22.53,14.56Z"></path> <rect class="fill-zip-3" height="7.2" width="1.97" x="19.02" y="17.56"></rect> <path class="fill-zip-3" d="M22.32,22.67h-.63v4.19H18.31V22.67h-.63a1.14,1.14,0,0,0-1.13,1.14V35a1.13,1.13,0,0,0,1.13,1.13h4.64A1.13,1.13,0,0,0,23.45,35V23.81A1.14,1.14,0,0,0,22.32,22.67Zm-.63,11.38H18.31V31h3.38Z"></path> </symbol> <symbol id="word" viewBox="0 0 40 40"> <path class="word-fill-1" d="M20.86,1.5h2.58V5c4.62,0,9.23,0,13.85,0A1.49,1.49,0,0,1,39,6.63c.07,8.5,0,17,0,25.52a5,5,0,0,1-.42,2.61,3.93,3.93,0,0,1-2.18.43c-4.32,0-8.64,0-13,0v3.45h-2.7C14.17,37.43,7.59,36.32,1,35.17Q1,20.07,1,5C7.62,3.81,14.24,2.68,20.86,1.5Z"></path> <path class="word-fill-2" d="M23.44,6.25H37.69V33.88H23.44V30.42H34.67V28.7H23.44V26.54H34.67V24.81H23.44V22.65H34.67V20.93H23.44V18.77H34.67V17H23.44V14.88H34.67V13.16H23.44V11H34.67V9.27H23.44Z"></path> <path class="word-fill-2" d="M9.92,13.88l2.46-.13c.57,2.91,1.16,5.82,1.78,8.72.49-3,1-6,1.55-9,.86,0,1.73-.08,2.59-.13-1,4.18-1.83,8.4-2.9,12.56-.72.38-1.8,0-2.65,0-.57-2.86-1.24-5.7-1.76-8.57-.5,2.79-1.16,5.55-1.74,8.32l-2.5-.15C6,21.78,5.2,18,4.53,14.2l2.22-.09c.44,2.75.95,5.49,1.34,8.24C8.69,19.52,9.32,16.7,9.92,13.88Z"></path> </symbol> <symbol id="txt" viewBox="0 0 40 40"> <path class="fill-txt-1" d="M32.1,1.09H.67v38H39V7.5Z"></path> <polygon class="fill-txt-2" points="39 7.47 32.6 7.47 32.1 1.09 39 7.47"></polygon> <path class="fill-txt-3" d="M33.78,30.22h.92a2.13,2.13,0,0,0,2.13-2.13V17.27a2.13,2.13,0,0,0-2.13-2.13H5.3a2.13,2.13,0,0,0-2.13,2.13V28.09A2.13,2.13,0,0,0,5.3,30.22H33.78Z"></path> <polygon class="fill-txt-4" points="9.47 19.4 9.47 17.74 15.96 17.74 15.96 19.4 13.54 19.4 13.54 27.53 11.9 27.53 11.9 19.4 9.47 19.4"></polygon> <polygon class="fill-txt-4" points="16.45 17.74 18.38 17.74 20.02 20.89 21.62 17.74 23.53 17.74 20.99 22.5 23.78 27.53 21.79 27.53 19.98 24.15 18.17 27.53 16.19 27.53 18.98 22.43 16.45 17.74"></polygon> <polygon class="fill-txt-4" points="24.04 19.4 24.04 17.74 30.53 17.74 30.53 19.4 28.11 19.4 28.11 27.53 26.46 27.53 26.46 19.4 24.04 19.4"></polygon> </symbol> <symbol id="media" viewBox="0 0 40 40"> <circle class="media-fill-1" cx="20" cy="20" r="19"></circle> <circle class="media-fill-2" cx="20" cy="20" r="15"></circle> <polygon class="media-fill-3" points="28.96 20 15.04 12.5 15.04 27.5 28.96 20"></polygon> </symbol> <symbol id="info-circle" viewBox="0 0 40 40"> <path d="M20,0A20,20,0,1,0,40,20,20,20,0,0,0,20,0Zm3.14,27.36c-1.51,2.27-3,4-5.63,4-1.76-.29-2.49-1.55-2.1-2.84l3.32-11a.52.52,0,0,0-.3-.64c-.25-.08-.73.23-1.14.69l-2,2.42a10.92,10.92,0,0,1,0-1.35c1.51-2.27,4-4.05,5.67-4.05A2.26,2.26,0,0,1,23,17.48L19.67,28.54a.52.52,0,0,0,.31.58c.25.08.76-.23,1.18-.69l2-2.42A10.84,10.84,0,0,1,23.14,27.41ZM22.69,13a2.23,2.23,0,0,1-2.3-2.29,2.3,2.3,0,0,1,4.6,0A2.23,2.23,0,0,1,22.69,13Z" class="fr-evenodd"></path> </symbol> <symbol id="alert_06"> <path d="M15,0C6.8,0,0,6.8,0,15s6.8,15,15,15s15-6.8,15-15S23.3,0,15,0z M15,22.5c-0.8,0-1.5-0.7-1.5-1.5 s0.7-1.5,1.5-1.5s1.5,0.7,1.5,1.5S15.8,22.5,15,22.5z M16.5,16c0,0.8-0.7,1.5-1.5,1.5s-1.5-0.7-1.5-1.5V9c0-0.8,0.7-1.5,1.5-1.5 s1.5,0.7,1.5,1.5V16z"/> </symbol>  <symbol id="timelineicon"> <path d="M12,8A4,4 0 0,1 16,12A4,4 0 0,1 12,16A4,4 0 0,1 8,12A4,4 0 0,1 12,8M3.05,13H1V11H3.05C3.5,6.83 6.83,3.5 11,3.05V1H13V3.05C17.17,3.5 20.5,6.83 20.95,11H23V13H20.95C20.5,17.17 17.17,20.5 13,20.95V23H11V20.95C6.83,20.5 3.5,17.17 3.05,13M12,5A7,7 0 0,0 5,12A7,7 0 0,0 12,19A7,7 0 0,0 19,12A7,7 0 0,0 12,5Z" /> </symbol>  <symbol id="alert-circle" viewBox="0 0 24.00 24.00"> <path d="M 12.9994,12.998L 10.9994,12.998L 10.9994,6.99805L 12.9994,6.99805M 12.9994,16.998L 10.9994,16.998L 10.9994,14.998L 12.9994,14.998M 11.9994,1.99805C 6.47639,1.99805 1.99939,6.47504 1.99939,11.998C 1.99939,17.5211 6.47639,21.998 11.9994,21.998C 17.5224,21.998 21.9994,17.5211 21.9994,11.998C 21.9994,6.47504 17.5224,1.99805 11.9994,1.99805 Z "/> </symbol>  <symbol id="ext" viewBox="0 0 40 40"> <polygon points="36 17.97 36 36 4 36 4 4 22.03 4 22.03 1 1 1 1 39 39 39 39 17.97 36 17.97" /> <polygon points="39 1 26.27 1 31 5.73 17.52 19.21 20.8 22.48 34.27 9 39 13.73 39 1" /> </symbol> <symbol id="presentation_01" viewBox="0 0 40 40"> <path d="M35,5.21H5A1.29,1.29,0,1,1,5,2.63h13.7V1.34a1.3,1.3,0,0,1,2.6,0V2.63H35a1.29,1.29,0,1,1,0,2.58Zm0,20.64H5V6.5H35ZM9,15.57a5.2,5.2,0,0,0,10.4,0h-5.2V10.4A5.19,5.19,0,0,0,9,15.57Zm14.33-5.2H22v1.29h1.3Zm0,2.58H22v1.29h1.3Zm0,2.58H22v1.29h1.3Zm0,2.58H22V19.4h1.3Zm0,2.58H22V22h1.3Zm7.78-10.32H24.58v1.29h6.48Zm0,2.58H24.58v1.29h6.48Zm0,2.58H24.58v1.29h6.48Zm0,2.58H24.58V19.4h6.48Zm0,2.58H24.58V22h6.48ZM16.46,32.31h2.93V25.85h1.3v6.45h2.88l-2.88-6.45h2.6l5.18,11.61H25.88L24.15,33.6H20.69V40h-1.3V33.6H15.88l-1.76,3.87H11.53L16.8,25.85h2.59Zm4.22-6.45Zm-1.3,0Z" class="fill-a"></path> </symbol> <symbol id="excel" viewBox="0 0 40 40"> <path class="fill-excel-1" d="M20.87,1.5h2.56V5c4.32,0,8.64,0,13,0a4,4,0,0,1,2.17.41A4,4,0,0,1,39,7.54Q39,18.78,39,30a19.69,19.69,0,0,1-.15,3.78c-.17.9-1.25.92-2,.95-4.47,0-8.95,0-13.43,0v3.89H20.76C14.18,37.43,7.59,36.32,1,35.17V5C7.63,3.81,14.25,2.67,20.87,1.5Z"></path> <path class="fill-excel-2" d="M23.44,6.25H37.68v27.2H23.44V30.85h3.45v-3H23.44V26.11h3.45v-3H23.44V21.36h3.45v-3H23.44V16.61h3.45v-3H23.44V11.86h3.45v-3H23.44Z"></path> <path class="fill-excel-1" d="M28.62,8.84h6v3h-6Z"></path> <path class="fill-excel-2" d="M13.79,12.88q1.46-.1,2.94-.18Q15,16.25,13.24,19.78c1.19,2.42,2.4,4.82,3.59,7.23l-3.12-.2a51,51,0,0,1-2.15-5.42c-.59,1.75-1.42,3.41-2.1,5.12-.95,0-1.89-.05-2.84-.09,1.11-2.17,2.18-4.36,3.32-6.52-1-2.22-2-4.4-3-6.61l2.85-.16c.64,1.69,1.35,3.35,1.88,5.08C12.21,16.38,13.06,14.66,13.79,12.88Z"></path> <path class="fill-excel-1" d="M28.62,13.59h6v3h-6Z"></path> <path class="fill-excel-1" d="M28.62,18.34h6v3h-6Z"></path> <path class="fill-excel-1" d="M28.62,23.08h6v3h-6Z"></path> <path class="fill-excel-1" d="M28.62,27.83h6v3h-6Z"></path> </symbol> <symbol id="epub" viewBox="0 0 40 40"> <path class="fill-epub-1" d="M32.64,1H1.45V38.68h38V7.36Z"></path> <polygon class="fill-epub-2" points="39.47 7.39 33.07 7.39 32.64 1 39.47 7.39"></polygon> <path class="fill-epub-3" d="M20,27.23,12.77,20,20,12.77l2.41,2.41L17.59,20,20,22.41l7.23-7.23-6.3-6.29a1.3,1.3,0,0,0-1.86,0L8.89,19.07a1.3,1.3,0,0,0,0,1.86L19.07,31.11a1.3,1.3,0,0,0,1.86,0L31.11,20.93a1.3,1.3,0,0,0,0-1.86l-1.47-1.48Z"></path> </symbol> <symbol id="imgft" viewBox="0 0 40 40"> <path class="fill-svgimgfile" d="M32.58,1H1.39V38.68h38V7.36Z"></path> <polygon class="fill-op-2" points="39.41 7.39 33.01 7.39 32.58 1 39.41 7.39"></polygon> <path class="fill-w" d="M8.52,15.32a4,4,0,1,1,4,4A4,4,0,0,1,8.52,15.32ZM33.27,33.25H7.73V29.18l4.79-4.07,3.19,2.71,9.58-8.14,8,6.78Z"></path> </symbol> <symbol id="sas" viewBox="0 0 40 40"> <title>SAS</title> <path class="fill-sas" d="M32.58,1H1.39V38.68h38V7.36Zm-15,6.32A10.77,10.77,0,0,1,20.38,7a8.72,8.72,0,0,1,8.22,5.71C26.85,9.84,21.74,9.22,19,11c-3.16,2-4.2,5.47-1.87,8.3,0,0,1.32,1.61,2.48,3,.24.29.29.33.52.61h0l.36.44a1.74,1.74,0,0,1-2.66,2.22l-.9-1.1-3.2-3.87C8.31,14.06,13.22,8.42,17.61,7.32Zm4.78,25.36c-5.06,1.27-9.63-1.37-11-5.39C13.15,30.16,18.26,30.78,21,29c3.16-2,4.2-5.46,1.87-8.29l-3.23-3.9c-.13-.15-.2-.25-.2-.25a1.61,1.61,0,0,1,.34-2.32A1.84,1.84,0,0,1,21,13.83a1.51,1.51,0,0,1,1.11.55l.43.54,3.75,4.53C31.69,26,26.78,31.58,22.39,32.68Z"></path> <polygon style="opacity: 0.2;" points="39.41 7.39 33.01 7.39 32.58 1 39.41 7.39"></polygon> </symbol> <symbol id="stats" viewBox="0 0 40 40"> <title>stats</title> <path class="fill-txt-3" d="M32.58,1H1.39V38.68h38V7.36ZM27.22,14.61h4V29.12h-4Zm-6,3.46h4V29.12h-4Zm-6-11h4v22.1h-4Zm-6,4.58h4V29.12h-4Zm25,21.61H6.2a1,1,0,0,1,0-2h28a1,1,0,0,1,0,2Z"></path> <polygon style="opacity: 0.3;" points="39.41 7.39 33.01 7.39 32.58 1 39.41 7.39"></polygon> </symbol> <symbol id="cdc-tv" viewBox="0 0 40 40"> <defs> <linearGradient id="linear-gradient" x1="-1374.15" y1="10.03" x2="-1354.09" y2="25.47" gradientTransform="matrix(-1, 0, 0, 1, -1343.57, 0)" gradientUnits="userSpaceOnUse"> <stop offset="0" stop-color="#b8bab9"></stop> <stop offset="1" stop-color="#414042"></stop> </linearGradient> </defs> <path d="M38.61,6.5H1.3A.29.29,0,0,0,1,6.78v23a.29.29,0,0,0,.29.29H18.48v.64a1.51,1.51,0,0,1-.15.67H11.08L8.77,32.81v.33H31.15v-.33l-2.3-1.41H21.62a1.72,1.72,0,0,1-.15-.72v-.59H38.61a.29.29,0,0,0,.29-.29v-23A.29.29,0,0,0,38.61,6.5Z"></path> <polygon style="fill:url(#linear-gradient);" points="37.78 7.61 2.13 7.61 2.13 28.92 37.78 28.8 37.78 7.61"></polygon> <rect class="fill-w" x="2.16" y="7.64" width="35.6" height="21.31"></rect> <rect class="fill-cdc-tv" x="2.12" y="7.51" width="35.8" height="21.57"></rect> <polygon class="fill-w" points="16.82 29.08 37.92 7.71 37.92 7.5 37.81 7.5 16.51 29.08 16.82 29.08"></polygon> <polygon class="fill-w" points="3.52 29.08 4.95 7.5 4.73 7.5 3.3 29.08 3.52 29.08"></polygon> <polygon class="fill-w" points="4.66 29.08 7.74 7.5 7.52 7.5 4.44 29.08 4.66 29.08"></polygon> <polygon class="fill-w" points="5.88 29.08 10.7 7.5 10.47 7.5 5.65 29.08 5.88 29.08"></polygon> <polygon class="fill-w" points="7.22 29.08 14.1 7.5 13.87 7.5 6.99 29.08 7.22 29.08"></polygon> <polygon class="fill-w" points="8.49 29.08 17.32 7.5 17.08 7.5 8.25 29.08 8.49 29.08"></polygon> <polygon class="fill-w" points="9.94 29.08 20.99 7.5 20.74 7.5 9.69 29.08 9.94 29.08"></polygon> <polygon class="fill-w" points="26.51 7.5 26.25 7.5 11.94 29.08 12.21 29.08 26.51 7.5"></polygon> <polygon class="fill-w" points="31.61 7.5 31.33 7.5 13.94 29.08 14.23 29.08 31.61 7.5"></polygon> <polygon class="fill-w" points="37.92 15.67 37.92 15.38 20.67 29.08 21.03 29.08 37.92 15.67"></polygon> <polygon class="fill-w" points="37.92 21.61 37.92 21.34 25.53 29.08 25.95 29.08 37.92 21.61"></polygon> <polygon class="fill-w" points="37.92 27.2 37.92 26.96 33.36 29.08 33.89 29.08 37.92 27.2"></polygon> <path class="fill-w" d="M10.14,22.51c-3.72,0-6.25-2.3-6.25-6a6,6,0,0,1,6.28-6.17,7,7,0,0,1,2.8.56v1.78a3.3,3.3,0,0,0-2.77-1.46c-2.24,0-3.51,2.06-3.51,5,0,3.13,1.19,5.35,3.75,5.35A4.3,4.3,0,0,0,13,20.66l.43.93A5.05,5.05,0,0,1,10.14,22.51Z"></path> <path class="fill-w" d="M22.31,16.43c0,4.6-2.83,4.92-5,4.92V11.44C19.53,11.44,22.31,11.71,22.31,16.43Zm-2.95,5.86a5.54,5.54,0,0,0,5.7-5.91c0-4.77-3.41-5.84-6-5.84H14.79V22.29Z"></path> <path class="fill-w" d="M32.69,22.51c-3.72,0-6.25-2.3-6.25-6a6,6,0,0,1,6.28-6.17,7,7,0,0,1,2.8.56v1.78a3.3,3.3,0,0,0-2.76-1.46c-2.25,0-3.52,2.06-3.52,5,0,3.13,1.19,5.35,3.75,5.35a4.3,4.3,0,0,0,2.53-.93l.43.93A5,5,0,0,1,32.69,22.51Z"></path> </symbol> <symbol id="flickr" viewBox="0 0 40 40"> <rect class="fill-flickr flr-bg" x="1" y="1" width="38" height="38" rx="6.23"></rect> <path class="fill-flickr flr-dot-1" d="M32.89,20a5.62,5.62,0,1,1-5.62-5.62A5.62,5.62,0,0,1,32.89,20Z"></path> <path class="fill-flickr flr-dot-2" d="M18.35,20a5.62,5.62,0,1,1-5.62-5.62A5.62,5.62,0,0,1,18.35,20Z"></path> </symbol>  <symbol id="pinterest" viewBox="0 0 40 40"> <circle class="fill-w" cx="20" cy="20" r="19"></circle> <path class="fill-pinterest" d="M20,1a19,19,0,0,0-6.92,36.69,18.15,18.15,0,0,1,.06-5.45l2.23-9.44A6.85,6.85,0,0,1,14.8,20c0-2.64,1.53-4.62,3.44-4.62A2.39,2.39,0,0,1,20.64,18c0,1.63-1,4.07-1.57,6.33a2.76,2.76,0,0,0,2.81,3.43c3.38,0,6-3.56,6-8.7,0-4.55-3.27-7.73-7.94-7.73a8.22,8.22,0,0,0-8.58,8.24A7.41,7.41,0,0,0,12.75,24a.57.57,0,0,1,.14.54c-.15.6-.47,1.9-.53,2.16s-.28.42-.64.25c-2.37-1.1-3.85-4.57-3.85-7.36,0-6,4.35-11.49,12.55-11.49,6.59,0,11.71,4.69,11.71,11,0,6.55-4.13,11.82-9.86,11.82a5.09,5.09,0,0,1-4.35-2.18s-1,3.62-1.18,4.51a21,21,0,0,1-2.37,5A19,19,0,1,0,20,1Z"></path> </symbol> <symbol id="social_govd" viewBox="0 0 40 40" xmlns:xlink="http://www.w3.org/1999/xlink"> <path d="M9.42,27.77h-3a5.23,5.23,0,0,1-2.6-.63A5.16,5.16,0,0,1,1,22.45C1,17.06,1,11.67,1,6.28A5.32,5.32,0,0,1,6.27,1c9.08,0,18.17,0,27.25,0A5.42,5.42,0,0,1,39,6.41q0,8,0,15.93a5.38,5.38,0,0,1-5.48,5.43H24.31a1.55,1.55,0,0,0-.93.28L6.93,39.19a1.2,1.2,0,0,1-2-.78,2,2,0,0,1,.22-.92q2-4.64,4.09-9.28Zm6.1-14,3.62,2.68a1.26,1.26,0,0,0,1.7,0l3.08-2.29.52-.38.16.17,4.31,5.19,4.14,5a.8.8,0,1,0,1.21-1l-6.73-8.11L25.74,12.8l.24-.19,8.62-6.4a1.28,1.28,0,1,0-1.53-2q-6.36,4.72-12.72,9.45a.5.5,0,0,1-.72,0q-5-3.77-10.11-7.51c-.91-.68-1.82-1.36-2.74-2a1.23,1.23,0,0,0-1.61.06,1.22,1.22,0,0,0-.3,1.51,2.1,2.1,0,0,0,.57.61l8.37,6.22.4.31-.21.28L6.26,22.4c-.22.27-.46.53-.66.81a.79.79,0,0,0,1.2,1A3,3,0,0,0,7,24l6.16-7.42Z" class="fill-govd"></path> </symbol>  <symbol id="social_round_bookmark" viewBox="0 0 40 40"> <path class="fill-bookmark" d="M20,1A19,19,0,1,0,39,20,19,19,0,0,0,20,1ZM29.8,29.8a1.67,1.67,0,0,1-1.09,1.56,1.53,1.53,0,0,1-.67.12A1.84,1.84,0,0,1,26.78,31l-6.71-6.45L13.37,31a1.86,1.86,0,0,1-1.26.5,1.55,1.55,0,0,1-.67-.14,1.67,1.67,0,0,1-1.09-1.56V10.2a1.68,1.68,0,0,1,1.09-1.56,1.71,1.71,0,0,1,.67-.14H28a1.71,1.71,0,0,1,.67.14A1.68,1.68,0,0,1,29.8,10.2Z"></path> </symbol> <symbol id="social_round_cdc-tv" viewBox="0 0 40 40"> <path class="fill-cdc-tv" d="M20,1A19,19,0,1,0,39,20,19,19,0,0,0,20,1Zm14.3,28H21.12v1.39a1.21,1.21,0,0,0,.12.55h5.55L28.55,32v.24H11.36V32l1.78-1.09H18.7a1,1,0,0,0,.12-.51V29H5.63a.27.27,0,0,1-.27-.27V11.05a.27.27,0,0,1,.27-.27H34.29a.27.27,0,0,1,.26.27V28.73A.27.27,0,0,1,34.29,29Z"></path> <path class="fill-cdc-tv" d="M17.9,15.6v7.62c1.69,0,3.87-.25,3.87-3.79S19.63,15.6,17.9,15.6Z"></path> <path class="fill-cdc-tv" d="M6.79,12V27.77H33.12V12ZM12.41,24.1c-2.85,0-4.8-1.76-4.8-4.61a4.64,4.64,0,0,1,4.83-4.74,5.26,5.26,0,0,1,2.15.43v1.37a2.53,2.53,0,0,0-2.12-1.12c-1.73,0-2.7,1.58-2.7,3.86s.91,4.11,2.88,4.11a3.24,3.24,0,0,0,1.94-.72l.33.72A3.84,3.84,0,0,1,12.41,24.1Zm7.09-.17H16v-9h3.28c2,0,4.61.82,4.61,4.48A4.26,4.26,0,0,1,19.5,23.93Zm10.24.17c-2.86,0-4.8-1.76-4.8-4.61a4.63,4.63,0,0,1,4.82-4.74,5.26,5.26,0,0,1,2.15.43v1.37a2.53,2.53,0,0,0-2.12-1.12c-1.72,0-2.7,1.58-2.7,3.86S28,23.4,30,23.4a3.24,3.24,0,0,0,1.94-.72l.33.72A3.83,3.83,0,0,1,29.74,24.1Z"></path> </symbol> <symbol id="social_round_email" viewBox="0 0 40 40"> <path class="fill-email" d="M20,1A19,19,0,1,0,39,20,19,19,0,0,0,20,1ZM32,11,20,20.71,8,11ZM8,13.56l6.58,5.33L8,26.06ZM8,29l8.11-8.85L20,23.29l3.87-3.14L32,29Zm24-2.94-6.58-7.17L32,13.56Z"></path> </symbol> <symbol id="social_round_fb" viewBox="0 0 40 40"> <circle class="fill-fb" cx="19.99" cy="20" r="19"></circle> <path class="fill-w" d="M30.9,24.42l.68-5.28H26.36V15.77c0-1.53.42-2.57,2.61-2.57h2.8V8.48a35.84,35.84,0,0,0-4.08-.21c-4,0-6.79,2.46-6.79,7v3.89H16.34v5.28H20.9V39a18.64,18.64,0,0,0,5.46-1.07V24.42Z"></path> </symbol> <symbol id="social_round_facebook" viewBox="0 0 40 40"> <circle class="fill-fb" cx="19.99" cy="20" r="19"></circle> <path class="fill-w" d="M30.9,24.42l.68-5.28H26.36V15.77c0-1.53.42-2.57,2.61-2.57h2.8V8.48a35.84,35.84,0,0,0-4.08-.21c-4,0-6.79,2.46-6.79,7v3.89H16.34v5.28H20.9V39a18.64,18.64,0,0,0,5.46-1.07V24.42Z"></path> </symbol> <symbol id="social_round_flickr" viewBox="0 0 40 40"> <circle class="fill-flickr flr-bg" cx="19.99" cy="20" r="19"></circle> <path class="fill-flickr flr-dot-1" d="M32.89,20a5.62,5.62,0,1,1-5.62-5.62A5.62,5.62,0,0,1,32.89,20Z"></path> <path class="fill-flickr flr-dot-2" d="M18.35,20a5.62,5.62,0,1,1-5.62-5.62A5.62,5.62,0,0,1,18.35,20Z"></path> </symbol> <svg id="social_round_googleplus" viewBox="0 0 40 40"> <path class="fill-googleplus" d="M20,1A19,19,0,1,0,39,20,19,19,0,0,0,20,1ZM14.55,29.5A9.5,9.5,0,1,1,20.94,13c-2,1.88-1.92,2-2.71,2.77a5.39,5.39,0,0,0-3.68-1.38,5.64,5.64,0,0,0,0,11.28c3.08,0,4.33-1.32,5.13-3.76H14.55V18.12h9.12C24.3,22.67,22.39,29.5,14.55,29.5Zm17.11-8.84V24H29.31V20.66H25.93V18.31h3.38V15h2.35v3.3H35v2.35Z"></path> </svg> <symbol id="social_round_govd" viewBox="0 0 40 40"> <path class="fill-govd" d="M20,1A19,19,0,1,0,39,20,19,19,0,0,0,20,1Zm8.43,25.94H22.69a.93.93,0,0,0-.58.18l-10.27,7a.75.75,0,0,1-1.24-.49,1.2,1.2,0,0,1,.14-.57c.84-1.93,1.7-3.86,2.55-5.79,0-.08.06-.16.11-.27H11.56a3.28,3.28,0,0,1-1.63-.4,3.24,3.24,0,0,1-1.78-2.93c0-3.36,0-6.72,0-10.08a3.32,3.32,0,0,1,3.28-3.29c5.67,0,11.34,0,17,0a3.37,3.37,0,0,1,3.4,3.38q0,5,0,9.94A3.36,3.36,0,0,1,28.42,26.94Z"></path> <path class="fill-govd" d="M28.16,12.21l-7.94,5.9a.32.32,0,0,1-.45,0l-6.31-4.69c-.56-.42-1.13-.85-1.7-1.26a.79.79,0,0,0-1,0,.76.76,0,0,0-.18.94,1.44,1.44,0,0,0,.35.39l5.23,3.88.24.19-.13.17-4.83,5.82c-.14.17-.29.33-.42.51a.48.48,0,0,0,.1.67.47.47,0,0,0,.65,0,1.14,1.14,0,0,0,.15-.16c1.28-1.54,2.56-3.09,3.85-4.63.47-.58,1-1.15,1.45-1.74.77.56,1.51,1.12,2.25,1.67a.81.81,0,0,0,1.07,0l1.92-1.43.32-.24a.47.47,0,0,1,.1.11c.9,1.07,1.79,2.15,2.69,3.23l2.58,3.11a.5.5,0,1,0,.75-.65c-1.39-1.69-2.8-3.37-4.2-5.06l-1.11-1.34.15-.12,5.38-4a.8.8,0,1,0-.95-1.27Z"></path> </symbol> <symbol id="social_round_instagram" viewBox="0 0 40 40"> <circle style="fill:url(#svg_ig_1);" cx="20" cy="20" r="20"></circle> <circle style="fill:url(#svg_ig_2);" cx="20" cy="20" r="20"></circle> <path class="fill-w" d="M20,5.5c-4,0-4.5,0-6.1,0.1c-1.6,0.1-2.6,0.3-3.6,0.7C9.4,6.7,8.5,7.2,7.7,8C6.9,8.8,6.4,9.7,6,10.6c-0.4,0.9-0.6,2-0.7,3.6c-0.1,1.6-0.1,2.1-0.1,6.1s0,4.5,0.1,6.1C5.4,28,5.6,29,6,30c0.4,1,0.9,1.8,1.7,2.6c0.8,0.8,1.6,1.3,2.6,1.7c0.9,0.4,2,0.6,3.6,0.7c1.6,0.1,2.1,0.1,6.1,0.1c4,0,4.5,0,6.1-0.1c1.6-0.1,2.6-0.3,3.6-0.7c1-0.4,1.8-0.9,2.6-1.7c0.8-0.8,1.3-1.6,1.7-2.6c0.4-0.9,0.6-2,0.7-3.6c0.1-1.6,0.1-2.1,0.1-6.1s0-4.5-0.1-6.1c-0.1-1.6-0.3-2.6-0.7-3.6c-0.4-1-0.9-1.8-1.7-2.6c-0.8-0.8-1.6-1.3-2.6-1.7c-0.9-0.4-2-0.6-3.6-0.7C24.5,5.6,24,5.5,20,5.5L20,5.5z M18.7,8.2c0.4,0,0.8,0,1.3,0c3.9,0,4.4,0,6,0.1c1.4,0.1,2.2,0.3,2.7,0.5c0.7,0.3,1.2,0.6,1.7,1.1c0.5,0.5,0.8,1,1.1,1.7c0.2,0.5,0.4,1.3,0.5,2.7c0.1,1.6,0.1,2,0.1,6s0,4.4-0.1,6c-0.1,1.4-0.3,2.2-0.5,2.7c-0.3,0.7-0.6,1.2-1.1,1.7c-0.5,0.5-1,0.8-1.7,1.1c-0.5,0.2-1.3,0.4-2.7,0.5c-1.6,0.1-2,0.1-6,0.1c-3.9,0-4.4,0-6-0.1c-1.4-0.1-2.2-0.3-2.7-0.5c-0.7-0.3-1.2-0.6-1.7-1.1c-0.5-0.5-0.8-1-1.1-1.7C8.3,28.5,8,27.7,8,26.3c-0.1-1.6-0.1-2-0.1-6s0-4.4,0.1-6c0.1-1.4,0.3-2.2,0.5-2.7c0.3-0.7,0.6-1.2,1.1-1.7c0.5-0.5,1-0.8,1.7-1.1c0.5-0.2,1.3-0.4,2.7-0.5C15.4,8.2,15.9,8.2,18.7,8.2L18.7,8.2z M27.9,10.7c-1,0-1.8,0.8-1.8,1.8c0,1,0.8,1.8,1.8,1.8s1.8-0.8,1.8-1.8S28.9,10.7,27.9,10.7L27.9,10.7z M20,12.7c-4.2,0-7.6,3.4-7.6,7.6s3.4,7.6,7.6,7.6c4.2,0,7.6-3.4,7.6-7.6S24.2,12.7,20,12.7L20,12.7z M20,15.4c2.7,0,4.9,2.2,4.9,4.9c0,2.7-2.2,4.9-4.9,4.9c-2.7,0-4.9-2.2-4.9-4.9C15.1,17.6,17.3,15.4,20,15.4z"></path> </symbol> <symbol id="social_round_ig" viewBox="0 0 40 40"> <circle style="fill:url(#svg_ig_1);" cx="20" cy="20" r="20"></circle> <circle style="fill:url(#svg_ig_2);" cx="20" cy="20" r="20"></circle> <path class="fill-w" d="M20,5.5c-4,0-4.5,0-6.1,0.1c-1.6,0.1-2.6,0.3-3.6,0.7C9.4,6.7,8.5,7.2,7.7,8C6.9,8.8,6.4,9.7,6,10.6c-0.4,0.9-0.6,2-0.7,3.6c-0.1,1.6-0.1,2.1-0.1,6.1s0,4.5,0.1,6.1C5.4,28,5.6,29,6,30c0.4,1,0.9,1.8,1.7,2.6c0.8,0.8,1.6,1.3,2.6,1.7c0.9,0.4,2,0.6,3.6,0.7c1.6,0.1,2.1,0.1,6.1,0.1c4,0,4.5,0,6.1-0.1c1.6-0.1,2.6-0.3,3.6-0.7c1-0.4,1.8-0.9,2.6-1.7c0.8-0.8,1.3-1.6,1.7-2.6c0.4-0.9,0.6-2,0.7-3.6c0.1-1.6,0.1-2.1,0.1-6.1s0-4.5-0.1-6.1c-0.1-1.6-0.3-2.6-0.7-3.6c-0.4-1-0.9-1.8-1.7-2.6c-0.8-0.8-1.6-1.3-2.6-1.7c-0.9-0.4-2-0.6-3.6-0.7C24.5,5.6,24,5.5,20,5.5L20,5.5z M18.7,8.2c0.4,0,0.8,0,1.3,0c3.9,0,4.4,0,6,0.1c1.4,0.1,2.2,0.3,2.7,0.5c0.7,0.3,1.2,0.6,1.7,1.1c0.5,0.5,0.8,1,1.1,1.7c0.2,0.5,0.4,1.3,0.5,2.7c0.1,1.6,0.1,2,0.1,6s0,4.4-0.1,6c-0.1,1.4-0.3,2.2-0.5,2.7c-0.3,0.7-0.6,1.2-1.1,1.7c-0.5,0.5-1,0.8-1.7,1.1c-0.5,0.2-1.3,0.4-2.7,0.5c-1.6,0.1-2,0.1-6,0.1c-3.9,0-4.4,0-6-0.1c-1.4-0.1-2.2-0.3-2.7-0.5c-0.7-0.3-1.2-0.6-1.7-1.1c-0.5-0.5-0.8-1-1.1-1.7C8.3,28.5,8,27.7,8,26.3c-0.1-1.6-0.1-2-0.1-6s0-4.4,0.1-6c0.1-1.4,0.3-2.2,0.5-2.7c0.3-0.7,0.6-1.2,1.1-1.7c0.5-0.5,1-0.8,1.7-1.1c0.5-0.2,1.3-0.4,2.7-0.5C15.4,8.2,15.9,8.2,18.7,8.2L18.7,8.2z M27.9,10.7c-1,0-1.8,0.8-1.8,1.8c0,1,0.8,1.8,1.8,1.8s1.8-0.8,1.8-1.8S28.9,10.7,27.9,10.7L27.9,10.7z M20,12.7c-4.2,0-7.6,3.4-7.6,7.6s3.4,7.6,7.6,7.6c4.2,0,7.6-3.4,7.6-7.6S24.2,12.7,20,12.7L20,12.7z M20,15.4c2.7,0,4.9,2.2,4.9,4.9c0,2.7-2.2,4.9-4.9,4.9c-2.7,0-4.9-2.2-4.9-4.9C15.1,17.6,17.3,15.4,20,15.4z"></path> </symbol> <symbol id="social_round_linkedin" viewBox="0 0 40 40"> <path class="fill-linkin" d="M20,1A19,19,0,1,0,39,20,19,19,0,0,0,20,1ZM13.58,31H8.92V16h4.66ZM11.25,14a2.7,2.7,0,1,1,2.7-2.7A2.7,2.7,0,0,1,11.25,14ZM31,31H26.36V23.73c0-1.73,0-4-2.42-4s-2.79,1.9-2.79,3.85V31H16.5V16H21v2.05H21a4.88,4.88,0,0,1,4.4-2.42c4.72,0,5.59,3.1,5.59,7.13Z"></path> </symbol> <symbol id="social_round_pinterest" viewBox="0 0 40 40"> <circle class="fill-w" cx="20" cy="20" r="19"></circle> <path class="fill-pinterest" d="M20,1a19,19,0,0,0-6.92,36.69,18.15,18.15,0,0,1,.06-5.45l2.23-9.44A6.85,6.85,0,0,1,14.8,20c0-2.64,1.53-4.62,3.44-4.62A2.39,2.39,0,0,1,20.64,18c0,1.63-1,4.07-1.57,6.33a2.76,2.76,0,0,0,2.81,3.43c3.38,0,6-3.56,6-8.7,0-4.55-3.27-7.73-7.94-7.73a8.22,8.22,0,0,0-8.58,8.24A7.41,7.41,0,0,0,12.75,24a.57.57,0,0,1,.14.54c-.15.6-.47,1.9-.53,2.16s-.28.42-.64.25c-2.37-1.1-3.85-4.57-3.85-7.36,0-6,4.35-11.49,12.55-11.49,6.59,0,11.71,4.69,11.71,11,0,6.55-4.13,11.82-9.86,11.82a5.09,5.09,0,0,1-4.35-2.18s-1,3.62-1.18,4.51a21,21,0,0,1-2.37,5A19,19,0,1,0,20,1Z"></path> </symbol> <symbol id="social_round_podcast" viewBox="0 0 40 40"> <path class="fill-podcast" d="M20,1A19,19,0,1,0,39,20,19,19,0,0,0,20,1Zm2.8,33.33a.67.67,0,0,1-.67.67H17.84a.67.67,0,0,1-.67-.67V23.2a.67.67,0,0,1,.67-.67h4.28a.67.67,0,0,1,.67.67ZM17.27,19.16A2.73,2.73,0,1,1,20,21.89,2.73,2.73,0,0,1,17.27,19.16Zm8,4.37a6.89,6.89,0,1,0-10.59-.16l-.44,2a8.61,8.61,0,1,1,11.54.05Zm1.56,5.72-.49-1.74-.08-.28a10.19,10.19,0,1,0-12.42,0l-.12.58-.35,1.5a12.16,12.16,0,1,1,13.46-.08Z"></path> </symbol> <symbol id="social_round_rss" viewBox="0 0 40 40"> <path class="fill-rss" d="M20,1A19,19,0,1,0,39,20,19,19,0,0,0,20,1ZM12.08,31.06a3.14,3.14,0,1,1,3.13-3.14A3.14,3.14,0,0,1,12.08,31.06Zm11.22-.34a1,1,0,0,1-.77.34h-2.2a1,1,0,0,1-1-.95A10.46,10.46,0,0,0,9.89,20.7a1,1,0,0,1-1-1v-2.2a1,1,0,0,1,.34-.77,1,1,0,0,1,.71-.28h.08A14.79,14.79,0,0,1,23.58,29.93,1.1,1.1,0,0,1,23.3,30.72Zm8.35,0a1,1,0,0,1-.76.33H28.56a1.05,1.05,0,0,1-1-1A18.7,18.7,0,0,0,9.92,12.47a1,1,0,0,1-1-1V9.1a1,1,0,0,1,.33-.75A1,1,0,0,1,10,8.06h0A23.2,23.2,0,0,1,31.94,30,1,1,0,0,1,31.65,30.73Z"></path> </symbol> <symbol id="social_round_syndication" viewBox="0 0 40 40"> <path class="fill-synd" d="M20,1A19,19,0,1,0,39,20,19,19,0,0,0,20,1Zm1.33,9.94a1,1,0,0,1,1.27-.71,10.47,10.47,0,0,1,2.37,1,10.11,10.11,0,0,1,4.83,6.42A1,1,0,0,1,29,18.89a1,1,0,0,1-1.24-.75A8.17,8.17,0,0,0,22,12.21,1,1,0,0,1,21.32,10.94Zm8,12.86a9,9,0,0,1-.66,1.36,10.13,10.13,0,0,1-7.55,5H21a1,1,0,0,1-1-.89,1,1,0,0,1,.89-1.15,8.1,8.1,0,0,0,6-4A7.31,7.31,0,0,0,27.45,23a1,1,0,0,1,1.91.76Zm-9-8.72a1,1,0,0,1,1.3-.66,5.91,5.91,0,0,1,3.85,3.94,1,1,0,0,1-.68,1.27,1,1,0,0,1-1.29-.69,3.86,3.86,0,0,0-2.52-2.57A1,1,0,0,1,20.39,15.08Zm-1.76.12a1,1,0,0,1-.48,1.37,4,4,0,0,0-2.1,2.67,1,1,0,0,1-1,.81.83.83,0,0,1-.22,0A1,1,0,0,1,14,18.8a6,6,0,0,1,3.22-4.07A1,1,0,0,1,18.63,15.2Zm-.8-4.15a1,1,0,0,1-.64,1.31A8.14,8.14,0,0,0,12.78,16a8,8,0,0,0-1,2.72,1,1,0,0,1-1,.85h-.18a1,1,0,0,1-.84-1.18A10,10,0,0,1,11,15a10.2,10.2,0,0,1,5.53-4.54A1,1,0,0,1,17.83,11.05ZM6.93,19H6.77a1,1,0,0,1-.86-1.17A14.11,14.11,0,0,1,14.84,6.9a1,1,0,0,1,1.33.6,1,1,0,0,1-.6,1.32,12.14,12.14,0,0,0-6.16,5.23A11.7,11.7,0,0,0,8,18.16,1,1,0,0,1,6.93,19Zm7.37,6.31-6-.84L19.8,19.85,15.2,31.23Zm6.12-1.44a3.89,3.89,0,0,0,2.94-2.17,1,1,0,0,1,1.38-.49,1,1,0,0,1,.49,1.37,5.93,5.93,0,0,1-4.51,3.32h-.15a1,1,0,0,1-.15-2Zm12.51,1.46a14.92,14.92,0,0,1-.86,1.75,14.11,14.11,0,0,1-11.24,7h-.07a1,1,0,0,1-.07-2.05A12,12,0,0,0,31,24.58a1,1,0,0,1,1.91.77ZM32.8,18a1,1,0,0,1-.24,0,1,1,0,0,1-1-.78,11.93,11.93,0,0,0-5.68-7.55,12.09,12.09,0,0,0-3-1.22,1,1,0,0,1-.73-1.26,1,1,0,0,1,1.26-.73,14.12,14.12,0,0,1,3.46,1.43,14,14,0,0,1,6.65,8.84A1,1,0,0,1,32.8,18Z"></path> </symbol> <symbol id="social_round_tumblr" viewBox="0 0 40 40"> <path class="fill-tumblr" d="M20,1A19,19,0,1,0,39,20,19,19,0,0,0,20,1Zm7.59,29.88a7.34,7.34,0,0,1-4.74,1.6h-.2c-6.14,0-7.47-4.5-7.47-7.14V18H12.75a.5.5,0,0,1-.5-.51V14.07a.86.86,0,0,1,.57-.81A6.46,6.46,0,0,0,17.1,7.31c0-.55.33-.83.82-.83h3.6A.51.51,0,0,1,22,7v5.85h4.21a.51.51,0,0,1,.51.51V17.5a.5.5,0,0,1-.51.5H22v6.77a1.89,1.89,0,0,0,1.81,2.16,5,5,0,0,0,1.64-.35,1.13,1.13,0,0,1,.65-.11c.18,0,.29.17.37.4l1.12,3.26C27.69,30.39,27.77,30.68,27.58,30.88Z"></path> </symbol> <symbol id="social_round_twitter" viewBox="0 0 40 40"> <circle class="fill-tw" cx="19.99" cy="20" r="19"></circle> <path class="fill-w" d="M15.59,29.65A13.77,13.77,0,0,0,29.46,15.79c0-.21,0-.42,0-.63a10,10,0,0,0,2.44-2.53,9.85,9.85,0,0,1-2.8.77,4.9,4.9,0,0,0,2.14-2.69,10,10,0,0,1-3.09,1.18,4.87,4.87,0,0,0-8.43,3.33,5,5,0,0,0,.12,1.11,13.8,13.8,0,0,1-10-5.09,4.88,4.88,0,0,0,1.51,6.51,5,5,0,0,1-2.21-.61v.06A4.88,4.88,0,0,0,13,22a5,5,0,0,1-1.29.17,4.53,4.53,0,0,1-.91-.09,4.87,4.87,0,0,0,4.55,3.38,9.77,9.77,0,0,1-6.05,2.09,8.82,8.82,0,0,1-1.16-.07,13.77,13.77,0,0,0,7.46,2.19"></path> </symbol> <symbol id="social_round_youtube" viewBox="0 0 40 40"> <path class="fill-youtube" d="M20,1A19,19,0,1,0,39,20,19,19,0,0,0,20,1ZM13.85,27V13l12.3,7Z"></path> </symbol> <symbol id="intranet-connects-cdc"> <style type="text/css"> .st0 { fill: #FFFFFF; } .st1 { fill: none; stroke: #FFFFFF; stroke-width: 2.1206; } .st2 { fill: #005DA9; } .st3 { fill: none; stroke: #FFFFFF; stroke-width: 1.8943; } .st4 { fill: #607171; } </style> <g> <rect x="1.3" y="9.6" class="st0" width="157.9" height="96.4"/> <rect x="1.3" y="9.6" class="st1" width="157.9" height="96.4"/> <rect x="2.8" y="11" class="st2" width="155" height="93.4"/> <polygon class="st0" points="66.5,104.5 157.8,11.9 157.8,11 157.3,11 65.1,104.5 "/> <polygon class="st0" points="8.8,104.5 15,11 14.1,11 7.9,104.5 "/> <polygon class="st0" points="13.8,104.5 27.1,11 26.1,11 12.8,104.5 "/> <polygon class="st0" points="19.1,104.5 39.9,11 39,11 18.1,104.5 "/> <polygon class="st0" points="24.9,104.5 54.7,11 53.7,11 23.9,104.5 "/> <polygon class="st0" points="30.4,104.5 68.6,11 67.6,11 29.3,104.5 "/> <polygon class="st0" points="36.7,104.5 84.5,11 83.4,11 35.6,104.5 "/> <polygon class="st0" points="108.4,11 107.3,11 45.3,104.5 46.5,104.5 "/> <polygon class="st0" points="130.5,11 129.3,11 54,104.5 55.2,104.5 "/> <polygon class="st0" points="157.8,46.4 157.8,45.2 83.1,104.5 84.7,104.5 "/> <polygon class="st0" points="157.8,72.1 157.8,71 104.2,104.5 106,104.5 "/> <polygon class="st0" points="157.8,96.4 157.8,95.3 138.1,104.5 140.3,104.5 "/> <g> <path class="st0" d="M37.5,76C21.4,76,10.4,66.1,10.4,50c0-15.7,11.7-26.7,27.2-26.7c4.1,0,8.7,0.8,12.2,2.4v7.7 c-1.7-2.3-5.2-6.3-12-6.3c-9.7,0-15.2,8.9-15.2,21.8c0,13.5,5.1,23.2,16.2,23.2c3.9,0,8.8-2,11-4.1l1.8,4.1 C49.5,73.7,45.6,76,37.5,76"/> <path class="st3" d="M37.5,76C21.4,76,10.4,66.1,10.4,50c0-15.7,11.7-26.7,27.2-26.7c4.1,0,8.7,0.8,12.2,2.4v7.7 c-1.7-2.3-5.2-6.3-12-6.3c-9.7,0-15.2,8.9-15.2,21.8c0,13.5,5.1,23.2,16.2,23.2c3.9,0,8.8-2,11-4.1l1.8,4.1 C49.5,73.7,45.6,76,37.5,76z"/> <path class="st0" d="M77.4,75.1c9.8,0,24.7-6.1,24.7-25.6c0-20.7-14.8-25.3-26-25.3H57.6v50.9H77.4z M90.2,49.7 C90.2,69.6,78,71,68.4,71V28C78.2,28,90.2,29.2,90.2,49.7"/> <path class="st3" d="M77.4,75.1c9.8,0,24.7-6.1,24.7-25.6c0-20.7-14.8-25.3-26-25.3H57.6v50.9H77.4z M90.2,49.7 C90.2,69.6,78,71,68.4,71V28C78.2,28,90.2,29.2,90.2,49.7z"/> <path class="st0" d="M135.2,76c-16.1,0-27.1-9.9-27.1-26.1c0-15.7,11.7-26.7,27.2-26.7c4.2,0,8.7,0.8,12.2,2.4v7.7 c-1.7-2.3-5.2-6.3-12-6.3c-9.7,0-15.2,8.9-15.2,21.8c0,13.5,5.1,23.2,16.2,23.2c3.9,0,8.8-2,11-4.1l1.8,4.1 C147.2,73.7,143.2,76,135.2,76"/> <path class="st3" d="M135.2,76c-16.1,0-27.1-9.9-27.1-26.1c0-15.7,11.7-26.7,27.2-26.7c4.2,0,8.7,0.8,12.2,2.4v7.7 c-1.7-2.3-5.2-6.3-12-6.3c-9.7,0-15.2,8.9-15.2,21.8c0,13.5,5.1,23.2,16.2,23.2c3.9,0,8.8-2,11-4.1l1.8,4.1 C147.2,73.7,143.2,76,135.2,76z"/> </g> </g> <circle fill="transparent" cx="291.9" cy="61.5" r="30.6"/> <path class="st4" d="M267.9,97.4c-8.5,8-20,12.9-32.6,12.9c-26.3,0-47.8-21.4-47.8-47.8c0-26.3,21.4-47.8,47.8-47.8 c12.6,0,24,4.9,32.6,12.9c3.7-2.6,7.9-4.7,12.4-6C269.1,9.4,253.1,1.7,235.3,1.7c-33.5,0-60.8,27.3-60.8,60.8s27.3,60.8,60.8,60.8 c17.8,0,33.8-7.7,44.9-19.9C275.8,102,271.6,100,267.9,97.4z"/> <g> <path class="st4" d="M255.5,62.4c0-20.4,16.5-36.9,37-36.9c20.4,0,37,16.5,37,36.9c0,20.5-16.5,37-37,37 C272,99.5,255.5,83,255.5,62.4z M316.4,62.5c0-13.6-10.7-24.6-24-24.6c-13.2,0-24,11-24,24.6c0,13.7,10.7,24.7,24,24.7 C305.7,87.2,316.4,76.1,316.4,62.5z"/> <path class="st4" d="M404.9,57.2V98h-13V60.3c0-12.4-9.7-22.5-21.8-22.5c-12,0-21.8,10.1-21.8,22.5V98h-13V27h13v10.5 c5.8-7.3,14.8-12,24.8-12C390.7,25.5,404.9,39.7,404.9,57.2z"/> <path class="st4" d="M482.9,57.2V98h-13V60.3c0-12.4-9.7-22.5-21.8-22.5c-12,0-21.8,10.1-21.8,22.5V98h-13V27h13v10.5 c5.8-7.3,14.8-12,24.8-12C468.7,25.5,482.9,39.7,482.9,57.2z"/> <path class="st4" d="M526.7,87.2c8.3,0,18.1-2.9,25.7-7.3l5.6,10.9c-9.4,5.4-20.9,8.7-31.3,8.7c-22.3,0-37.4-14.3-37.5-37 c0-20.4,15.9-37,35.5-37c19.6,0,35.5,16.5,35.5,36.9c0,2.4-0.3,4.8-0.7,7.1H503C505.5,80.9,514.3,87.2,526.7,87.2z M546.8,57.5 c-2.1-11.2-11.2-19.7-22.1-19.7c-10.9,0-20,8.5-22.1,19.7H546.8z"/> <path class="st4" d="M622.7,77.1l8.9,8.2c-6.7,8.5-17.2,14-29,14c-20.4,0-37-16.5-37-36.9c0-20.4,16.5-36.9,37-36.9 c11.8,0,22.2,5.5,29,14l-8.9,8.2c-4.5-5.6-12-9.9-20-9.9c-13.1,0-24,11-24,24.6c0,13.6,10.9,24.6,24,24.6 C610.8,87.1,618.2,82.8,622.7,77.1z"/> <path class="st4" d="M689,95.8c-10.7,4.7-22.8,5.3-31.4,0c-6.2-3.8-10-10.4-10-19.6V39.3H634V27h13.6V7.1h13V27h22.7v12.3h-22.7 v35.5c0,4.9,1.4,8.4,4.5,10.4c4.9,3,12.9,1.9,20.1-0.9L689,95.8z"/> <path class="st4" d="M690.5,89.6l5.7-10.3c4.6,2.9,13.8,7.6,24.9,7.5c8.3-0.1,16.2-2.9,16.1-8.5c-0.1-6.5-8-8-15.5-9.3 c-13.2-2.4-27.8-6.8-27.9-22.4c-0.1-14.9,15.6-21.3,28.4-21.4c9.7-0.1,21.6,4.3,29.5,9.7L746,45.1c-5.1-3.6-15.1-7.6-23.6-7.5 c-8.8,0.1-14.5,3.5-14.4,8.6c0.1,6.8,7.5,8.5,13.8,9.8c15.7,3.1,29.5,6.8,29.6,21.6c0.1,15.8-18,21.6-29.9,21.6 C711.1,99.3,698.6,94.9,690.5,89.6z"/> </g> </symbol> <symbol id="intranet-connects-text"> <style type="text/css"> .st0 { fill: #FFFFFF; } .st1 { fill: none; stroke: #FFFFFF; stroke-width: 2.1206; } .st2 { fill: #005DA9; } .st3 { fill: none; stroke: #FFFFFF; stroke-width: 1.8943; } .st4 { fill: #607171; } </style> <g> <rect x="1.3" y="9.6" class="st0" width="157.9" height="96.4"/> <rect x="1.3" y="9.6" class="st1" width="157.9" height="96.4"/> <rect x="2.8" y="11" class="st2" width="155" height="93.4"/> <polygon class="st0" points="66.5,104.5 157.8,11.9 157.8,11 157.3,11 65.1,104.5 "/> <polygon class="st0" points="8.8,104.5 15,11 14.1,11 7.9,104.5 "/> <polygon class="st0" points="13.8,104.5 27.1,11 26.1,11 12.8,104.5 "/> <polygon class="st0" points="19.1,104.5 39.9,11 39,11 18.1,104.5 "/> <polygon class="st0" points="24.9,104.5 54.7,11 53.7,11 23.9,104.5 "/> <polygon class="st0" points="30.4,104.5 68.6,11 67.6,11 29.3,104.5 "/> <polygon class="st0" points="36.7,104.5 84.5,11 83.4,11 35.6,104.5 "/> <polygon class="st0" points="108.4,11 107.3,11 45.3,104.5 46.5,104.5 "/> <polygon class="st0" points="130.5,11 129.3,11 54,104.5 55.2,104.5 "/> <polygon class="st0" points="157.8,46.4 157.8,45.2 83.1,104.5 84.7,104.5 "/> <polygon class="st0" points="157.8,72.1 157.8,71 104.2,104.5 106,104.5 "/> <polygon class="st0" points="157.8,96.4 157.8,95.3 138.1,104.5 140.3,104.5 "/> <g> <path class="st0" d="M37.5,76C21.4,76,10.4,66.1,10.4,50c0-15.7,11.7-26.7,27.2-26.7c4.1,0,8.7,0.8,12.2,2.4v7.7 c-1.7-2.3-5.2-6.3-12-6.3c-9.7,0-15.2,8.9-15.2,21.8c0,13.5,5.1,23.2,16.2,23.2c3.9,0,8.8-2,11-4.1l1.8,4.1 C49.5,73.7,45.6,76,37.5,76"/> <path class="st3" d="M37.5,76C21.4,76,10.4,66.1,10.4,50c0-15.7,11.7-26.7,27.2-26.7c4.1,0,8.7,0.8,12.2,2.4v7.7 c-1.7-2.3-5.2-6.3-12-6.3c-9.7,0-15.2,8.9-15.2,21.8c0,13.5,5.1,23.2,16.2,23.2c3.9,0,8.8-2,11-4.1l1.8,4.1 C49.5,73.7,45.6,76,37.5,76z"/> <path class="st0" d="M77.4,75.1c9.8,0,24.7-6.1,24.7-25.6c0-20.7-14.8-25.3-26-25.3H57.6v50.9H77.4z M90.2,49.7 C90.2,69.6,78,71,68.4,71V28C78.2,28,90.2,29.2,90.2,49.7"/> <path class="st3" d="M77.4,75.1c9.8,0,24.7-6.1,24.7-25.6c0-20.7-14.8-25.3-26-25.3H57.6v50.9H77.4z M90.2,49.7 C90.2,69.6,78,71,68.4,71V28C78.2,28,90.2,29.2,90.2,49.7z"/> <path class="st0" d="M135.2,76c-16.1,0-27.1-9.9-27.1-26.1c0-15.7,11.7-26.7,27.2-26.7c4.2,0,8.7,0.8,12.2,2.4v7.7 c-1.7-2.3-5.2-6.3-12-6.3c-9.7,0-15.2,8.9-15.2,21.8c0,13.5,5.1,23.2,16.2,23.2c3.9,0,8.8-2,11-4.1l1.8,4.1 C147.2,73.7,143.2,76,135.2,76"/> <path class="st3" d="M135.2,76c-16.1,0-27.1-9.9-27.1-26.1c0-15.7,11.7-26.7,27.2-26.7c4.2,0,8.7,0.8,12.2,2.4v7.7 c-1.7-2.3-5.2-6.3-12-6.3c-9.7,0-15.2,8.9-15.2,21.8c0,13.5,5.1,23.2,16.2,23.2c3.9,0,8.8-2,11-4.1l1.8,4.1 C147.2,73.7,143.2,76,135.2,76z"/> </g> </g> <circle fill="transparent" cx="291.9" cy="61.5" r="30.6"/> <path class="st4" d="M267.9,97.4c-8.5,8-20,12.9-32.6,12.9c-26.3,0-47.8-21.4-47.8-47.8c0-26.3,21.4-47.8,47.8-47.8 c12.6,0,24,4.9,32.6,12.9c3.7-2.6,7.9-4.7,12.4-6C269.1,9.4,253.1,1.7,235.3,1.7c-33.5,0-60.8,27.3-60.8,60.8s27.3,60.8,60.8,60.8 c17.8,0,33.8-7.7,44.9-19.9C275.8,102,271.6,100,267.9,97.4z"/> <g> <path class="st4" d="M255.5,62.4c0-20.4,16.5-36.9,37-36.9c20.4,0,37,16.5,37,36.9c0,20.5-16.5,37-37,37 C272,99.5,255.5,83,255.5,62.4z M316.4,62.5c0-13.6-10.7-24.6-24-24.6c-13.2,0-24,11-24,24.6c0,13.7,10.7,24.7,24,24.7 C305.7,87.2,316.4,76.1,316.4,62.5z"/> <path class="st4" d="M404.9,57.2V98h-13V60.3c0-12.4-9.7-22.5-21.8-22.5c-12,0-21.8,10.1-21.8,22.5V98h-13V27h13v10.5 c5.8-7.3,14.8-12,24.8-12C390.7,25.5,404.9,39.7,404.9,57.2z"/> <path class="st4" d="M482.9,57.2V98h-13V60.3c0-12.4-9.7-22.5-21.8-22.5c-12,0-21.8,10.1-21.8,22.5V98h-13V27h13v10.5 c5.8-7.3,14.8-12,24.8-12C468.7,25.5,482.9,39.7,482.9,57.2z"/> <path class="st4" d="M526.7,87.2c8.3,0,18.1-2.9,25.7-7.3l5.6,10.9c-9.4,5.4-20.9,8.7-31.3,8.7c-22.3,0-37.4-14.3-37.5-37 c0-20.4,15.9-37,35.5-37c19.6,0,35.5,16.5,35.5,36.9c0,2.4-0.3,4.8-0.7,7.1H503C505.5,80.9,514.3,87.2,526.7,87.2z M546.8,57.5 c-2.1-11.2-11.2-19.7-22.1-19.7c-10.9,0-20,8.5-22.1,19.7H546.8z"/> <path class="st4" d="M622.7,77.1l8.9,8.2c-6.7,8.5-17.2,14-29,14c-20.4,0-37-16.5-37-36.9c0-20.4,16.5-36.9,37-36.9 c11.8,0,22.2,5.5,29,14l-8.9,8.2c-4.5-5.6-12-9.9-20-9.9c-13.1,0-24,11-24,24.6c0,13.6,10.9,24.6,24,24.6 C610.8,87.1,618.2,82.8,622.7,77.1z"/> <path class="st4" d="M689,95.8c-10.7,4.7-22.8,5.3-31.4,0c-6.2-3.8-10-10.4-10-19.6V39.3H634V27h13.6V7.1h13V27h22.7v12.3h-22.7 v35.5c0,4.9,1.4,8.4,4.5,10.4c4.9,3,12.9,1.9,20.1-0.9L689,95.8z"/> <path class="st4" d="M690.5,89.6l5.7-10.3c4.6,2.9,13.8,7.6,24.9,7.5c8.3-0.1,16.2-2.9,16.1-8.5c-0.1-6.5-8-8-15.5-9.3 c-13.2-2.4-27.8-6.8-27.9-22.4c-0.1-14.9,15.6-21.3,28.4-21.4c9.7-0.1,21.6,4.3,29.5,9.7L746,45.1c-5.1-3.6-15.1-7.6-23.6-7.5 c-8.8,0.1-14.5,3.5-14.4,8.6c0.1,6.8,7.5,8.5,13.8,9.8c15.7,3.1,29.5,6.8,29.6,21.6c0.1,15.8-18,21.6-29.9,21.6 C711.1,99.3,698.6,94.9,690.5,89.6z"/> </g> </symbol> </svg>  <script>var MP = {  Version: '3.1.1.1', SrcLang: 'en',  UrlLang: 'mp_js_current_lang', SrcUrl: decodeURIComponent('mp_js_orgin_url'), oSite: decodeURIComponent('mp_js_origin_baseUrl'), tSite: decodeURIComponent('mp_js_translated_baseUrl'),  init: function() { if (MP.oSite.indexOf('p_js_') == 1) { MP.SrcUrl = window.top.document.location.href; MP.oSite = MP.tSite = window.top.document.location.host; MP.UrlLang = MP.SrcLang; } }, switchLanguage: function(url,pref,sync) { var sync = sync; var oSite=MP.oSite.replace('http://','').replace('https://','').replace(/\/?$/, ''); var tSite=MP.tSite.replace('http://','').replace('https://','').replace(/\/?$/, ''); url=url.replace('http://','').replace('https://','').replace(/\/?$/, ''); if(sync && (typeof MpStorage !== 'undefined')&&(typeof MpStorage.updatePref !== 'undefined')){ if(pref){ var lang = pref.substring(0, 2); pref = lang == MP.UrlLang ? MP.SrcLang+pref.substring(2):pref; } MpStorage.updatePref(url,pref); } setTimeout(function() { var script = document.createElement('SCRIPT'); if (url == oSite) { tSite = tSite.split(/[/?#]/)[0]; script.src = location.protocol + '//' + tSite +'?1023749634;' + encodeURIComponent(location.href); } else { url = url.split(/[/?#]/)[0]; script.src = location.protocol + '//' + url +'?1023749632;' + encodeURIComponent(MP.SrcUrl); } var target = document.getElementsByTagName('script')[0]; target.parentNode.insertBefore(script, target); }, 500); return false; }, switchToLang: function(url) { if(window.top.location.href == url){ if((typeof MpStorage !== 'undefined')&&(typeof MpStorage.updatePref !== 'undefined')) MpStorage.updatePref(MP.oSite,MP.SrcLang); }else{ window.top.location.href = url; } }  };</script><script>function switchLanguage(lang) { MP.UrlLang='mp_js_current_lang'; MP.SrcUrl=decodeURIComponent('mp_js_orgin_url'); MP.oSite=decodeURIComponent('mp_js_origin_baseUrl'); MP.tSite=decodeURIComponent('mp_js_translated_baseUrl'); MP.init(); } </script><script src="/TemplatePackage/contrib/libs/d3/d3.min.js"></script> <script src="/TemplatePackage/contrib/libs/c3/c3.js"></script> <script src="/TemplatePackage/contrib/libs/mmwr/mmwr_metrics.min.js"></script> <script>window.CDC.Policy.External.init();</script> <script> s.pageName=document.title; siteCatalyst.setChannel("MMWR"); siteCatalyst.setLevel1("OS"); siteCatalyst.setLevel2("OSD"); </script> <script> window.shortTitle = "Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 ― United States, January–July 2022"; window.pageOptions = window.pageOptions || {}; window.pageOptions.navigation = window.pageOptions.navigation || { fourthLevelCollapsed: false, showFourthLevel: true }; </script> <script> window.pageOptions.navigation.breadcrumbs = { mode: 'auto', showCurrentPage: false , prefix: [{"text":"CDC","href":"https:\/\/www.cdc.gov\/"}] }; </script> <script> window.CDC.tp4.public.appInit( window.pageOptions ); </script> </body> </html>